JP4538638B2 - Selenophosphate chloride and method for producing the same - Google Patents
Selenophosphate chloride and method for producing the same Download PDFInfo
- Publication number
- JP4538638B2 JP4538638B2 JP2005517906A JP2005517906A JP4538638B2 JP 4538638 B2 JP4538638 B2 JP 4538638B2 JP 2005517906 A JP2005517906 A JP 2005517906A JP 2005517906 A JP2005517906 A JP 2005517906A JP 4538638 B2 JP4538638 B2 JP 4538638B2
- Authority
- JP
- Japan
- Prior art keywords
- cdcl
- nmr
- compound
- acid amide
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 title claims description 74
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 title claims description 31
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 239000011669 selenium Substances 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 15
- 229910052711 selenium Inorganic materials 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- DVWQNBIUTWDZMW-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalen-2-ol Chemical class C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=CC=CC2=C1 DVWQNBIUTWDZMW-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 10
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 4
- 239000013256 coordination polymer Substances 0.000 description 130
- 239000000243 solution Substances 0.000 description 114
- 238000006243 chemical reaction Methods 0.000 description 102
- 150000001408 amides Chemical class 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 68
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- 150000001875 compounds Chemical class 0.000 description 55
- 239000002904 solvent Substances 0.000 description 44
- 230000003287 optical effect Effects 0.000 description 41
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 33
- -1 selenophosphoric acid chlorides Chemical class 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 32
- 238000004949 mass spectrometry Methods 0.000 description 32
- 238000002844 melting Methods 0.000 description 31
- 230000008018 melting Effects 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000000862 absorption spectrum Methods 0.000 description 30
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 29
- 150000001412 amines Chemical class 0.000 description 26
- 229910052698 phosphorus Inorganic materials 0.000 description 21
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 20
- 101150065749 Churc1 gene Proteins 0.000 description 20
- 102100038239 Protein Churchill Human genes 0.000 description 20
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- 238000000921 elemental analysis Methods 0.000 description 17
- 229910003002 lithium salt Inorganic materials 0.000 description 17
- 159000000002 lithium salts Chemical class 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 7
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical class C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XQJHRCVXRAJIDY-UHFFFAOYSA-N aminophosphine Chemical compound PN XQJHRCVXRAJIDY-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 4
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 4
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 4
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 4
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 4
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 4
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 4
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 3
- XBWOPGDJMAJJDG-ZETCQYMHSA-N (1s)-1-cyclohexylethanamine Chemical compound C[C@H](N)C1CCCCC1 XBWOPGDJMAJJDG-ZETCQYMHSA-N 0.000 description 3
- RTCUCQWIICFPOD-VIFPVBQESA-N (1s)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-VIFPVBQESA-N 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 3
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 3
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 3
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 3
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 3
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 3
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 3
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- 238000011914 asymmetric synthesis Methods 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 229940125876 compound 15a Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 150000004696 coordination complex Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 3
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 150000003613 toluenes Chemical class 0.000 description 3
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 3
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SDPWJCPUJAHXAM-UHFFFAOYSA-N NP(C1=CC=CC=C1)=[Se] Chemical compound NP(C1=CC=CC=C1)=[Se] SDPWJCPUJAHXAM-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- AEWJYTXWCUNEPP-UHFFFAOYSA-N 1-chlorocycloocta-1,3-diene;rhodium Chemical class [Rh].ClC1=CC=CCCCC1 AEWJYTXWCUNEPP-UHFFFAOYSA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- RUJHATQMIMUYKD-UHFFFAOYSA-N 2-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(CCN)=CC=CC2=C1 RUJHATQMIMUYKD-UHFFFAOYSA-N 0.000 description 1
- JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 1
- YKUUYQKLTCFDCB-AFMDSPMNSA-N C[C@@H](c1cccc2c1cccc2)N[P@](C1CCCCC1)(c1ccccc1)=S Chemical compound C[C@@H](c1cccc2c1cccc2)N[P@](C1CCCCC1)(c1ccccc1)=S YKUUYQKLTCFDCB-AFMDSPMNSA-N 0.000 description 1
- 0 C[C@@](C1CCCCC1)N[P@](*)(c1ccccc1)=S Chemical compound C[C@@](C1CCCCC1)N[P@](*)(c1ccccc1)=S 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N binaphthyl group Chemical group C1(=CC=CC2=CC=CC=C12)C1=CC=CC2=CC=CC=C12 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZGYXPWYDQRJWQR-UHFFFAOYSA-N chloro-cyclohexyl-phenyl-selanylidene-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(=[Se])(Cl)C1CCCCC1 ZGYXPWYDQRJWQR-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000002641 lithium Chemical group 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 150000003008 phosphonic acid esters Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
Description
本発明は、新規なセレノホスフィン酸アミド、セレノリン酸アミド、セレノリン酸塩化物及びそれらの製造方法に関する。 The present invention relates to novel selenophosphinic acid amides, selenophosphoric acid amides, selenophosphoric acid chlorides and methods for producing them.
従来、リン原子にセレン原子が結合しているセレノホスフィン酸及びセレノリン酸では、セレン原子以外にも水素原子、フェニル基等のアリール基、メチル基等のアルキル基、又はメトキシ基等のアルコキシ基がリン原子に結合しており、例えばハロゲン化銀写真感光材料の分光感度を高めるためのセレン増感剤として用いられている(例えば、特許文献1〜7参照。)。
本発明者らは、鋭意研究を重ねることによって、新規で、かつ空気中で安定なセレノホスフィン酸アミド、セレノリン酸アミド及びセレノリン酸塩化物を見出した。さらに、本発明者らは、セレノホスフィン酸アミド及びセレノリン酸アミドが例えばハロゲン化銀写真感光材料の分光感度を高めるセレン増感剤として有用であり、セレノリン酸塩化物が例えばラセミ体から光学活性化合物を分離するためのキラル識別化剤として有用であることを見出した。本発明はこうして得られた知見に基づくものであり、空気中で安定なセレノホスフィン酸アミド、セレノリン酸アミド、セレノリン酸塩化物及びそれらの製造方法を提供する。 The inventors of the present invention have discovered selenophosphinic acid amides, selenophosphoric acid amides, and selenophosphoric acid chlorides that are new and stable in air by intensive research. Furthermore, the present inventors have found that selenophosphinic acid amides and selenophosphoric acid amides are useful as selenium sensitizers that increase the spectral sensitivity of silver halide photographic light-sensitive materials, for example, and selenophosphoric acid chlorides are optically active compounds from, for example, racemates. It was found to be useful as a chiral discriminating agent for separating. The present invention is based on the knowledge thus obtained, and provides selenophosphinic amides, selenophosphoric acid amides, selenophosphoric acid chlorides which are stable in air, and methods for producing them.
本発明の一態様では、下記一般式(7)で示される構造を有し、(R)体又は(S)体であるセレノリン酸塩化物が提供される。このセレノリン酸塩化物は、空気中で安定で、光学活性を発揮する。 In one embodiment of the present invention, there is provided a selenophosphate chloride having a structure represented by the following general formula (7) and being an (R) isomer or an (S) isomer. This selenophosphate chloride is stable in air and exhibits optical activity.
本発明の別の態様では、前記一般式(7)で示される構造を有し、(R)体又は(S)体であるセレノリン酸塩化物の製造方法であって、三塩化リン、トリエチルアミン、下記一般式(8)で示される構造を有し(R)体又は(S)体であるビナフトール誘導体、及びセレンを相互に反応させるセレノリン酸塩化物の製造方法が提供される。このセレノリン酸塩化物の製造方法によれば、空気中で安定で、光学活性を発揮するセレノリン酸塩化物の製造が容易である。
In another aspect of the present invention, there is provided a process for producing a selenophosphate acid chloride having the structure represented by the general formula (7), which is an (R) isomer or an (S) isomer, comprising phosphorus trichloride, triethylamine, A binaphthol derivative which has a structure represented by the following general formula (8) and is an (R) isomer or (S) isomer, and a method for producing a selenophosphate chloride by reacting selenium with each other are provided. According to this method for producing a selenophosphate, it is easy to produce a selenophosphate that is stable in air and exhibits optical activity.
本実施形態に係るセレノホスフィン酸アミドは、下記一般式(1)で示される構造を有する化合物である。 The selenophosphinic acid amide according to this embodiment is a compound having a structure represented by the following general formula (1).
前記R1からR3において、アルキル基としてはメチル基、1−フェニルエチル基、1−(1−ナフチル)エチル基、1−シクロヘキシルエチル等のエチル基、イソプロピル基等のプロピル基又はtert−ブチル基等のブチル基が挙げられる。ここで、アルキル基には、シクロヘキシル基等のシクロアルキル基が含まれる。
In R 1 to R 3 , the alkyl group is a methyl group, 1-phenylethyl group, 1- (1-naphthyl) ethyl group, ethyl group such as 1-cyclohexylethyl, propyl group such as isopropyl group, or tert-butyl. And a butyl group such as a group. Here, the alkyl group includes a cycloalkyl group such as a cyclohexyl group.
このセレノホスフィン酸アミドは空気中で安定であり、ハロゲン化銀写真感光材料の分光感度を高めるためのセレン増感剤、及び不斉合成反応等の各種反応における配位子や配位子供給源として有用である。さらに、セレノホスフィン酸アミドは、前記一般式(1)中のR2及びR3から選ばれる少なくとも一方のキラルなアルキル基に起因して不斉中心を2個以上含有し、光学活性を発揮する。ここで、キラルなアルキル基とは、(R)配置及び(S)配置を有するアルキル基のことである。キラルなアルキル基としては、1−フェニルエチル基、1−(1−ナフチル)エチル基又は1−シクロヘキシルエチル基が挙げられる。従って、セレノホスフィン酸アミドは、3価のリン(P)を有する光学活性化合物の原料としても有用である。This selenophosphinic acid amide is stable in the air, and is used as a selenium sensitizer for enhancing the spectral sensitivity of silver halide photographic light-sensitive materials and as a ligand and a ligand source in various reactions such as asymmetric synthesis reactions. Useful. Further, the selenophosphinic acid amide contains two or more asymmetric centers due to at least one chiral alkyl group selected from R 2 and R 3 in the general formula (1), and exhibits optical activity. . Here, the chiral alkyl group is an alkyl group having an (R) configuration and an (S) configuration. Examples of the chiral alkyl group include a 1-phenylethyl group, a 1- (1-naphthyl) ethyl group, and a 1-cyclohexylethyl group. Accordingly, selenophosphinic acid amide is also useful as a raw material for optically active compounds having trivalent phosphorus (P).
例えば、下記反応式(9)に示すように、セレノホスフィン酸アミドにトリブチルホスフィン等の還元剤を反応させることにより、医薬品の中間体の合成に用いられるアミノホスフィンが得られる。このアミノホスフィンは光学活性を発揮し、不斉合成における光学活性配位子供給源としても用いられるとともに、金属原子に配位結合して金属錯体を形成する。この金属錯体は、鏡像異性体を有する化合物の合成反応の触媒として用いられることにより、合成される化合物の立体配置の選択性を容易に高める。 For example, as shown in the following reaction formula (9), by reacting a selenophosphinic acid amide with a reducing agent such as tributylphosphine, an aminophosphine used for the synthesis of a pharmaceutical intermediate can be obtained. This aminophosphine exhibits optical activity, is used as an optically active ligand supply source in asymmetric synthesis, and forms a metal complex by coordination with a metal atom. This metal complex is easily used as a catalyst for the synthesis reaction of a compound having an enantiomer, thereby easily enhancing the selectivity of the configuration of the synthesized compound.
セレノホスフィン酸アミドは、下記一般式(2)で示される構造を有するセレノホスフィン酸塩化物と、下記一般式(3)で示される構造を有するアミンのリチウム塩とを反応させることにより製造される(下記反応式(10)参照)。ここで、セレノホスフィン酸塩化物及びアミンのリチウム塩は、それぞれ光学活性体でもよいしラセミ体でもよい。 A selenophosphinic acid amide is produced by reacting a selenophosphinic acid chloride having a structure represented by the following general formula (2) with a lithium salt of an amine having a structure represented by the following general formula (3). (See the following reaction formula (10)). Here, the selenophosphinic chloride and the lithium salt of amine may be optically active or racemic.
このセレノホスフィン酸アミドの製造方法では、セレノホスフィン酸アミドは2つの立体異性体の混合物であるジアステレオマーとして得られる。このため、セレノホスフィン酸アミドを製造した後、再結晶やクロマトグラフィを用いた分離によって各立体異性体を分離する精製操作を行うことが好ましい。
本実施形態に係るセレノリン酸アミドは、下記一般式(4)で示される構造を有する化合物である。In this method for producing selenophosphinic acid amide, selenophosphinic acid amide is obtained as a diastereomer which is a mixture of two stereoisomers. For this reason, after manufacturing selenophosphinic acid amide, it is preferable to perform the refinement | purification operation which isolate | separates each stereoisomer by separation using recrystallization or chromatography.
The selenophosphoric acid amide according to the present embodiment is a compound having a structure represented by the following general formula (4).
前記R4及びR5において、ハロゲン原子としては塩素原子が挙げられ、アルキル基としてはメチル基、1−フェニルエチル基、1−(1−ナフチル)エチル基、1−シクロヘキシルエチル基等のエチル基、1−メチルプロピル基又は1,2−ジメチルプロピル基等のプロピル基が挙げられる。アリール基としてはフェニル基が挙げられ、アルコキシ基としてはメンチルオキシ基が挙げられ、シリル基としてはトリメチルシリル基が挙げられる。アルキルピペリジル基としては2−メチルピペリジル基が挙げられる。セレノリン酸アミドは空気中で安定であり、セレノホスフィン酸アミドと同様に、前記セレン増感剤、不斉合成反応等の各種反応における配位子や配位子供給源、及び医薬品の中間体の合成に用いられるアミノホスフィンの原料として有用である。ここで、セレノリン酸アミド由来のアミノホスフィンは、セレノリン酸アミドにトリブチルホスフィン等の還元剤を反応させることにより得られる。セレノリン酸アミドは、一般式(4)中のR5が2−メチルピペリジル基を示す構造を有することが好ましい。また、セレノリン酸アミドは、一般式(4)中のR5が−NR6R7を示し、R6が水素原子又は1−フェニルエチル基を示し、R7が1−フェニルエチル基、1−(1−ナフチル)エチル基、1−メチルプロピル又は1,2−ジメチルプロピル基を示す構造を有することが好ましい。これらセレノリン酸アミドの空気中での安定性は特に高い。In R 4 and R 5 , the halogen atom includes a chlorine atom, and the alkyl group includes an ethyl group such as a methyl group, a 1-phenylethyl group, a 1- (1-naphthyl) ethyl group, and a 1-cyclohexylethyl group. , A propyl group such as a 1-methylpropyl group or a 1,2-dimethylpropyl group. The aryl group includes a phenyl group, the alkoxy group includes a menthyloxy group, and the silyl group includes a trimethylsilyl group. Examples of the alkyl piperidyl group include a 2-methyl piperidyl group. Selenophosphoric acid amide is stable in the air, and, like selenophosphinic acid amide, synthesis of ligands and ligand sources in various reactions such as the selenium sensitizer, asymmetric synthesis reaction, and intermediates of pharmaceuticals It is useful as a raw material for aminophosphines used in Here, aminophosphine derived from selenophosphoric acid amide can be obtained by reacting selenophosphoric acid amide with a reducing agent such as tributylphosphine. The selenophosphoric acid amide preferably has a structure in which R 5 in the general formula (4) represents a 2-methylpiperidyl group. In the selenophosphoric acid amide, R 5 in the general formula (4) represents —NR 6 R 7 , R 6 represents a hydrogen atom or a 1-phenylethyl group, R 7 represents a 1-phenylethyl group, 1- It preferably has a structure showing a (1-naphthyl) ethyl group, 1-methylpropyl or 1,2-dimethylpropyl group. These selenophosphoric acid amides have particularly high stability in air.
セレノリン酸アミドは、前記一般式(4)中のR5がキラルなアルキルピペリジル基を示す構造を有することが好ましい。ここで、キラルなアルキルピペリジル基とは、キラルなアルキル基を有するピペリジル基のことである。また、セレノリン酸アミドは、前記一般式(4)中のR5が−NR6R7を示し、R6及びR7から選ばれる少なくとも一方がキラルなアルキル基を示す構造を有することが好ましい。これらセレノリン酸アミドは、キラルなアルキルピペリジル基又はキラルなアルキル基に起因して不斉中心を1個以上含有し、光学活性をそれぞれ発揮する。キラルなアルキルピペリジル基としては2−メチルピペリジル基が挙げられる。一方、キラルなアルキル基としては1−フェニルエチル基、1−(1−ナフチル)エチル基、1−メチルプロピル基又は1,2−ジメチルプロピル基が挙げられる。光学活性を発揮するセレノリン酸アミド(以下、光学活性セレノリン酸アミドという。)は、セレノホスフィン酸アミドと同様に、前記光学活性化合物の原料として有用である。光学活性セレノリン酸アミドから得られるアミノホスフィンは、セレノホスフィン酸アミドから得られるアミノホスフィンと同様に、光学活性配位子供給源として用いられる他に、金属原子と金属錯体を形成して鏡像異性体を有する化合物の合成反応の触媒として用いられる。The selenophosphoric acid amide preferably has a structure in which R 5 in the general formula (4) represents a chiral alkylpiperidyl group. Here, the chiral alkylpiperidyl group is a piperidyl group having a chiral alkyl group. Further, the selenophosphoric acid amide preferably has a structure in which R 5 in the general formula (4) represents —NR 6 R 7 and at least one selected from R 6 and R 7 represents a chiral alkyl group. These selenophosphoric acid amides contain one or more asymmetric centers due to a chiral alkylpiperidyl group or a chiral alkyl group, and each exhibit optical activity. Examples of the chiral alkylpiperidyl group include a 2-methylpiperidyl group. On the other hand, examples of the chiral alkyl group include a 1-phenylethyl group, a 1- (1-naphthyl) ethyl group, a 1-methylpropyl group, and a 1,2-dimethylpropyl group. A selenophosphoric acid amide exhibiting optical activity (hereinafter referred to as an optically active selenophosphoric acid amide) is useful as a raw material for the optically active compound, like the selenophosphinic acid amide. Aminophosphine obtained from optically active selenophosphoric acid amide can be used as an optically active ligand source in the same manner as aminophosphine obtained from selenophosphinic acid amide. It is used as a catalyst for a synthesis reaction of a compound having
セレノリン酸アミドは、下記一般式(5)で示される構造を有するセレノリン酸塩化物と、下記一般式(6)で示される構造を有するアミンとを反応させることにより製造される(下記反応式(11)参照)。 A selenophosphoric acid amide is produced by reacting a selenophosphoric acid chloride having a structure represented by the following general formula (5) with an amine having a structure represented by the following general formula (6) (the following reaction formula ( 11)).
R5−M …(6)
(式中、R5は−NR6R7又はアルキルピペリジル基を示し、Mは水素原子又はリチウム原子を示す。R6は水素原子又はアルキル基を示し、R7はアルキル基を示す。)
R 5 -M (6)
(In the formula, R 5 represents —NR 6 R 7 or an alkylpiperidyl group, M represents a hydrogen atom or a lithium atom, R 6 represents a hydrogen atom or an alkyl group, and R 7 represents an alkyl group.)
光学活性セレノリン酸アミドは、セレノリン酸塩化物と、前記一般式(6)中のR5がキラルなアルキルピペリジル基を示すアミンとを、前記セレノリン酸アミドと同様に反応させることにより製造される。また、光学活性セレノリン酸アミドは、セレノリン酸塩化物と、前記一般式(6)中のR5が−NR6R7を示し、R6及びR7から選ばれる少なくとも一方がキラルなアルキル基を示すアミンとを、前記セレノリン酸アミドと同様に反応させることにより製造される。ここで、アミンは光学活性体でもよいしラセミ体でもよい。これらの場合、光学活性セレノリン酸アミドはジアステレオマーとして得られるために、前記セレノホスフィン酸アミドと同様の精製操作を行うことが好ましい。
本実施形態に係るセレノリン酸塩化物は、下記一般式(7)で示される構造を有し、(R)体又は(S)体の化合物である。The optically active selenophosphoric acid amide is produced by reacting a selenophosphoric acid chloride with an amine in which R 5 in the general formula (6) represents a chiral alkylpiperidyl group in the same manner as the selenophosphoric acid amide. The optically active selenophosphoric acid amide includes selenophosphoric acid chloride, R 5 in the general formula (6) represents —NR 6 R 7 , and at least one selected from R 6 and R 7 has a chiral alkyl group. It is produced by reacting the amine shown in the same manner as the selenophosphoric acid amide. Here, the amine may be an optically active substance or a racemate. In these cases, since the optically active selenophosphoric acid amide is obtained as a diastereomer, it is preferable to perform the same purification operation as that of the selenophosphinic acid amide.
The selenophosphate chloride according to the present embodiment has a structure represented by the following general formula (7), and is a (R) -form or (S) -form compound.
前記R8において、ハロゲン原子としては塩素原子が挙げられ、アルキル基としてはメチル基、1−フェニルエチル基、1−(1−ナフチル)エチル基、1−シクロヘキシルエチル基等のエチル基、1−メチルプロピル基又は1,2−ジメチルプロピル基等のプロピル基が挙げられる。アリール基としてはフェニル基が挙げられ、アルコキシ基としてはメンチルオキシ基が挙げられ、シリル基としてはトリメチルシリル基が挙げられる。このセレノリン酸塩化物は空気中で安定であるうえに、水中でも安定である。さらに、セレノリン酸塩化物は(R)体又は(S)体に起因して光学活性を発揮する。セレノリン酸塩化物は、ラセミ体から光学活性化合物を分離するためのキラル識別化剤、及び前記光学活性セレノリン酸アミドの原料として有用である。セレノリン酸塩化物は、R8が水素原子を示す構造を有することが、空気中及び水中での安定性が特に高いために好ましい。In R 8 , the halogen atom may be a chlorine atom, the alkyl group may be an ethyl group such as a methyl group, 1-phenylethyl group, 1- (1-naphthyl) ethyl group, 1-cyclohexylethyl group, 1- Examples thereof include a propyl group such as a methylpropyl group or a 1,2-dimethylpropyl group. The aryl group includes a phenyl group, the alkoxy group includes a menthyloxy group, and the silyl group includes a trimethylsilyl group. This selenophosphate is stable in air and stable in water. Furthermore, the selenophosphate chloride exhibits optical activity due to the (R) isomer or the (S) isomer. The selenophosphate chloride is useful as a chiral discriminating agent for separating an optically active compound from a racemate and a raw material for the optically active selenophosphoric acid amide. It is preferable that the selenophosphate chloride has a structure in which R 8 represents a hydrogen atom because the stability in air and water is particularly high.
セレノリン酸塩化物は、三塩化リン、トリエチルアミン、下記一般式(8)で示される構造を有し(R)体又は(S)体であるビナフトール誘導体、及びセレンを相互に反応させることにより製造される(下記反応式(12)参照)。ここで、(R)体のセレノリン酸塩化物を製造するときには(R)体のビナフトール誘導体が原料として用いられ、(S)体のセレノリン酸塩化物を製造するときには(S)体のビナフトール誘導体が原料として用いられる。ビナフトール誘導体としては、R8が水素原子を示す1,1’−ビ−2−ナフトール(別名:β−ビナフトール)、R8が塩素原子を示す3,3’−ジクロロ−1,1’−ビ−2−ナフトールが挙げられる。Selenophosphate chloride is produced by reacting phosphorus trichloride, triethylamine, a binaphthol derivative having a structure represented by the following general formula (8), which is (R) or (S), and selenium. (See the following reaction formula (12)). Here, when producing the (R) selenophosphate chloride, the (R) binaphthol derivative is used as a raw material, and when producing the (S) selenophosphate chloride, the (S) binaphthol derivative is Used as a raw material. The binaphthol derivative, R 8 represents a hydrogen atom 1,1'-bi-2-naphthol (aka: beta-binaphthol), 3,3'-dichloro-1,1'-bi R 8 represents a chlorine atom -2-naphthol.
従って、本実施形態に係るセレノホスフィン酸アミドは前記一般式(1)で示される構造を有する新規化合物であり、本実施形態に係るセレノリン酸アミドは前記一般式(4)で示される構造を有する新規化合物である。これらセレノホスフィン酸アミド及びセレノリン酸アミドは空気中で安定であり、例えば前記セレン増感剤として有用である。また、本実施形態に係るセレノリン酸塩化物は前記一般式(7)で示される構造を有し、(R)体又は(S)体の新規化合物であり、空気中及び水中で安定である。セレノリン酸塩化物は例えば前記キラル識別化剤として有用である。 Therefore, the selenophosphinic acid amide according to the present embodiment is a novel compound having the structure represented by the general formula (1), and the selenophosphoric acid amide according to the present embodiment has the structure represented by the general formula (4). It is a new compound. These selenophosphinic acid amides and selenophosphoric acid amides are stable in the air and are useful, for example, as the selenium sensitizer. In addition, the selenophosphate chloride according to the present embodiment has a structure represented by the general formula (7), is a novel compound of (R) form or (S) form, and is stable in air and water. Selenophosphates are useful, for example, as the chiral discriminating agent.
さらに、前記セレノホスフィン酸塩化物と前記アミンのリチウム塩との反応性は高いことから、反応式(10)の反応は触媒を用いることなく進行する。このため、このセレノホスフィン酸アミドの製造方法によれば、空気中で安定で、光学活性を発揮するセレノホスフィン酸アミドの製造が容易である。また、前記セレノリン酸塩化物と前記アミンとの反応性も高いことから、反応式(11)の反応も触媒を用いることなく進行する。このため、このセレノリン酸アミドの製造方法によれば、空気中で安定なセレノリン酸アミドの製造が容易である。加えて、前記三塩化リン、トリエチルアミン、ビナフトール誘導体、及びセレンの反応性も高いことから、反応式(12)の反応も触媒を用いることなく進行する。このため、セレノリン酸塩化物の製造方法によれば、空気中及び水中で安定で、光学活性を発揮するセレノリン酸塩化物の製造が容易である。 Furthermore, since the reactivity of the selenophosphinic chloride and the lithium salt of the amine is high, the reaction of the reaction formula (10) proceeds without using a catalyst. For this reason, according to this method for producing selenophosphinic acid amide, it is easy to produce selenophosphinic acid amide that is stable in air and exhibits optical activity. In addition, since the reactivity between the selenophosphate and the amine is high, the reaction of the reaction formula (11) proceeds without using a catalyst. For this reason, according to this method for producing selenophosphoric acid amide, it is easy to produce selenophosphoric acid amide that is stable in the air. In addition, since the phosphorus trichloride, triethylamine, binaphthol derivative, and selenium have high reactivity, the reaction of the reaction formula (12) proceeds without using a catalyst. For this reason, according to the manufacturing method of a selenophosphate compound, the manufacture of the selenophosphate compound which is stable in the air and water and exhibits optical activity is easy.
以下、実施例を挙げて本発明をさらに具体的に説明する。尚、以下の説明において、Phはフェニル基を示す。
(実施例1) 0℃で、(S)-1-フェニルエチルアミン0.28mL(2.2mmol)を5mLのTHFに溶解させた。次いで、該THFにブチルリチウム1.25mL(1.6Msolution in hexane;2.0mmol)を加えた後、THFを10分間撹拌して(S)-1-フェニルエチルアミンのリチウム塩を得た。ここで、(S)-1-フェニルエチルアミンのリチウム塩は前記アミンのリチウム塩であり、THFに溶解した状態で得られた。このTHF溶液を溶液Aとする。一方、セレノホスフィン酸塩化物としてのP-1,1-ジメチルエチル-P-フェニルセレノホスフィン酸クロリド0.560g(2.00mmol)を5mLのTHFに溶解させた。このTHF溶液を溶液Bとする。続いて、0℃で溶液Aを溶液Bに加えて反応溶液を調製した後、該反応溶液を25℃にまで加熱した後に2時間撹拌した。次に、反応溶液に対しジクロロメタン抽出を行い、ジクロロメタン層からなる抽出液を得た。次いで、抽出液の水洗、硫酸マグネシウムを用いた抽出液からの水の除去、抽出液の濾過及び濾液の濃縮を順に行った後、濃縮された濾液から溶媒を留去して残渣を得た。続いて、残渣をシリカゲルカラムクロマトグラフィ(ヘキサン:ジクロロメタン=1:1)で精製し、無色固体の化合物1a(Rf=0.40)及び無色固体の化合物1b(Rf=0.30)を得た。これら化合物1a及び1bの構造解析を行った。結果を以下に記載する。Hereinafter, the present invention will be described more specifically with reference to examples. In the following description, Ph represents a phenyl group.
Example 1 At 0 ° C., 0.28 mL (2.2 mmol) of (S) -1-phenylethylamine was dissolved in 5 mL of THF. Next, 1.25 mL (1.6 Msolution in hexane; 2.0 mmol) of butyl lithium was added to the THF, and then the THF was stirred for 10 minutes to obtain a lithium salt of (S) -1-phenylethylamine. Here, the lithium salt of (S) -1-phenylethylamine is the lithium salt of the amine and was obtained in a state dissolved in THF. This THF solution is designated as Solution A. On the other hand, P-1,1-dimethylethyl-P-phenylselenophosphinic chloride 0.560 g (2.00 mmol) as selenophosphinic acid chloride was dissolved in 5 mL of THF. This THF solution is designated as Solution B. Subsequently, the solution A was added to the solution B at 0 ° C. to prepare a reaction solution, and then the reaction solution was heated to 25 ° C. and then stirred for 2 hours. Next, the reaction solution was extracted with dichloromethane to obtain an extract composed of a dichloromethane layer. Subsequently, the extract was washed with water, water was removed from the extract using magnesium sulfate, the extract was filtered, and the filtrate was concentrated, and then the solvent was distilled off from the concentrated filtrate to obtain a residue. Subsequently, the residue was purified by silica gel column chromatography (hexane: dichloromethane = 1: 1) to obtain a colorless solid compound 1a (Rf = 0.40) and a colorless solid compound 1b (Rf = 0.30). The structures of these compounds 1a and 1b were analyzed. The results are described below.
(化合物1a)
<赤外吸収スペクトル(KBr錠剤)> 3287, 3086, 3066, 3045, 3029,2968, 2952, 2943, 2925, 2899, 2863, 1493, 1472, 1453, 1435, 1411, 1390, 1373,1362, 1312, 1282,1205, 1115, 1100, 1061, 1034, 1012, 1000, 972, 940, 842, 809,783, 745, 699, 627cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.11(d,3JH-P=17.1Hz,9H,CCH3),1.32(d,J=6.8Hz,3H,CHCH3中のCH3), 2.40(s,broad,1H,NH),4.78-4.87(m,1H,CHCH3中のCH), 7.26-7.53(m,8H,Ar), 8.06-8.11(m,2H,Ar).、 13C-NMR(CDCl3):δ24.5(CHCH3中のCH3),25.0(CCH3中のCH3), 35.6(d,1JC-P=56.2Hz,CCH3においてCH3に結合するC),52.5(CHCH3中のCH), 126.6(Ar), 127.3(Ar), 127.7(d,JC-P=11.6Hz,Ar),128.7(Ar), 131.5(d,4JC-P=3.3Hz,Ar), 132.4(d,1JC-P=78.6Hz,Ar),133.3(d,JC-P=9.9Hz,Ar), 145.3(d,JC-P=7.4Hz,Ar).、 31P-NMR(CDCl3):δ79.0(1JP-Se=750.2Hz).、 77Se-NMR(CDCl3):δ-369.2(d,1JSe-P=750.2Hz).
<質量分析> MS (EI) m/z 365 (M+).
<元素分析> Anal. Calcd for C18H24NPSe(364.32):C,59.34;H,6.64;N,3.84. Found:C,59.23;H,6.49;N,3.71.
(化合物1b)
<赤外吸収スペクトル(KBr錠剤)> 3346, 3078, 3060, 3020, 2999,2973, 2961, 2946, 2922, 2905, 2866, 1603, 1493, 1472, 1448, 1436, 1405, 1391,1367, 1343, 1308, 1293, 1276, 1203, 1189, 1102, 1082, 1070, 1022, 1011, 999,957, 907, 848, 809, 763, 750, 696, 627cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.19(d,3JH-P=17.1Hz,9H,CCH3),1.61(d,J=6.3Hz,3H,CHCH3中のCH3), 2.29(s,broad,1H,NH),4.40-4.50(m,1H,CHCH3中のCH), 7.19-7.38(m,8H,Ar), 7.47-7.73(m,2H,Ar).、 13C-NMR(CDCl3):δ25.0(CCH3中のCH3),25.8(d,2JC-P=3.3Hz,CHCH3中のCH3),35.2(d,1JC-P=56.2Hz,CCH3においてCH3に結合するC),52.3(CHCH3中のCH), 126.2(Ar), 126.9(Ar), 127.3(d,JC-P=12.4Hz,Ar),128.4(Ar), 130.2(d,1JC-P=81.1Hz,Ar), 131.3(d,JC-P=2.5Hz,Ar),133.8(d,JC-P=10.8Hz,Ar), 145.1(d,JC-P=5.8Hz,Ar).、 31P-NMR(CDCl3):δ81.3(1JP-Se=741.1Hz).、 77Se-NMR(CDCl3):δ-335.4(d,1JSe-P=741.1Hz).
<質量分析> MS (EI) m/z 365 (M+).
<元素分析> Anal. Calcd for C18H24NPSe(364.32):C,59.34;H,6.64;N,3.84. Found:C,59.23;H,6.49;N,3.71.(Compound 1a)
<Infrared absorption spectrum (KBr tablet)> 3287, 3086, 3066, 3045, 3029, 2968, 2952, 2943, 2925, 2899, 2863, 1493, 1472, 1453, 1435, 1411, 1390, 1373,1362, 1312, 1282,1205, 1115, 1100, 1061, 1034, 1012, 1000, 972, 940, 842, 809,783, 745, 699, 627cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.11 (d, 3 J HP = 17.1 Hz, 9 H, CCH 3 ), 1.32 (d, J = 6.8 Hz , 3H, CH 3 in CHCH 3), 2.40 (s, broad, 1H, NH), 4.78-4.87 (m, 1H, CH in CHCH 3), 7.26-7.53 (m, 8H, Ar), 8.06- . 8.11 (m, 2H, Ar ), 13 C-NMR (CDCl 3): δ24.5 (CH 3 in CHCH 3), (CH 3 in CCH 3) 25.0, 35.6 (d , 1 J CP = 56.2 Hz, C bonded to CH 3 in CCH 3 ), 52.5 (CH in CHCH 3 ), 126.6 (Ar), 127.3 (Ar), 127.7 (d, J CP = 11.6 Hz, Ar), 128.7 (Ar), 131.5 (d, 4 J CP = 3.3Hz, Ar), 132.4 (d, 1 J CP = 78.6Hz, Ar), 133.3 (d, J CP = 9.9Hz, Ar), 145.3 (d, J CP = 7.4Hz , Ar)., 31 P-NMR (CDCl 3 ): δ 79.0 ( 1 J P-Se = 750.2 Hz)., 77 Se-NMR (CDCl 3 ): δ-369.2 (d, 1 J Se-P = 750.2Hz).
<Mass spectrometry> MS (EI) m / z 365 (M + ).
<Elemental Analysis> Anal. Calcd for C 18 H 24 NPSe (364.32): C, 59.34; H, 6.64; N, 3.84. Found: C, 59.23; H, 6.49; N, 3.71.
(Compound 1b)
<Infrared absorption spectrum (KBr tablet)> 3346, 3078, 3060, 3020, 2999,2973, 2961, 2946, 2922, 2905, 2866, 1603, 1493, 1472, 1448, 1436, 1405, 1391,1367, 1343, 1308, 1293, 1276, 1203, 1189, 1102, 1082, 1070, 1022, 1011, 999,957, 907, 848, 809, 763, 750, 696, 627cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.19 (d, 3 J HP = 17.1 Hz, 9 H, CCH 3 ), 1.61 (d, J = 6.3 Hz , 3H, CH 3 in CHCH 3), 2.29 (s, broad, 1H, NH), 4.40-4.50 (m, 1H, CH in CHCH 3), 7.19-7.38 (m, 8H, Ar), 7.47- . 7.73 (m, 2H, Ar ), 13 C-NMR (CDCl 3): δ25.0 (CH 3 in CCH 3), 25.8 (d, 2 J CP = 3.3Hz, CH 3 in CHCH 3), 35.2 (d, 1 J CP = 56.2 Hz, C binding to CH 3 in CCH 3 ), 52.3 (CH in CHCH 3 ), 126.2 (Ar), 126.9 (Ar), 127.3 (d, J CP = 12.4 Hz , Ar), 128.4 (Ar), 130.2 (d, 1 J CP = 81.1Hz, Ar), 131.3 (d, J CP = 2.5Hz, Ar), 133.8 (d, J CP = 10.8Hz, Ar), 145.1 (d, J CP = 5.8 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 81.3 ( 1 J P-Se = 741.1 Hz)., 77 Se-NMR (CDCl 3 ): δ-335.4 ( d, 1 J Se-P = 741.1Hz).
<Mass spectrometry> MS (EI) m / z 365 (M + ).
<Elemental Analysis> Anal. Calcd for C 18 H 24 NPSe (364.32): C, 59.34; H, 6.64; N, 3.84. Found: C, 59.23; H, 6.49; N, 3.71.
以上の結果より、化合物1aは下記式(13)に示した構造を有しており、(RP,S)-P-1,1-ジメチルエチル-P-フェニル-N-1-フェニルエチルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は34%(収量:0.251g,0.69mmol)であり、融点は128〜130℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-40°であった。From the above results, compound 1a has the structure represented by the following formula (13), and (R P , S) -P-1,1-dimethylethyl-P-phenyl-N-1-phenylethylseleno Identified as phosphinic acid amide. The yield of this selenophosphinic acid amide is 34% (yield: 0.251 g, 0.69 mmol), the melting point is 128 to 130 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 40 °.
(化合物2a)
<赤外吸収スペクトル(KBr錠剤)> 3248, 3058, 3022, 2969, 2927,2869, 1493, 1466, 1454, 1435, 1418, 1383, 1365, 1314, 1294, 1277, 1254, 1208,1183, 1160, 1119, 1100, 1083, 1065, 1026, 997, 959, 910, 886, 833, 752, 697,674cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.86(dd,J=7.0Hz,3JP-Se=20.3Hz,3H,PCHCH3中のCH3),1.13(dd,J=6.8Hz,3JP-Se=19.5Hz,3H,PCHCH3中のCH3),1.29(d,J=6.3Hz,3H,NCHCH3中のCH3), 1.99(s,broad,1H,NH),2.18-2.31(m,1H,PCH), 4.64-4.72(m,1H,NCH), 7.24-7.54(m,8H,Ar),8.02-8.07(m,2H,Ar).、 13C-NMR(CDCl3):δ16.5(PCHCH3中のCH3),16.6(PCHCH3中のCH3), 24.8(d,3JC-P=3.3Hz,NCHCH3中のCH3),32.6(d,1JC-P=61.2Hz,PCH), 52.3(NCH), 126.5(Ar),127.3(Ar), 128.2(d,JC-P=11.6Hz,Ar), 128.6(Ar), 131.7(d,4JC-P=2.5Hz,Ar),132.2(d,JC-P=10.8Hz,Ar), 133.1(Ar;One half of the signal isoverlapping with another signal), 145.0(d,JC-P=7.4Hz,Ar).、 31P-NMR(CDCl3):δ74.1(1JP-Se=745.6Hz).、 77Se-NMR(CDCl3):δ-386.8(d,1JSe-P=745.6Hz).
<質量分析> MS (EI) m/z 351 (M+).
(化合物2b)
<赤外吸収スペクトル(KBr錠剤)> 3291, 3079, 3060, 3023, 2976,2927, 2881, 2871, 1491, 1452, 1438, 1412, 1387, 1365, 1308, 1298, 1278, 1243,1204, 1119, 1103, 1085, 1067, 1021, 999, 962, 929, 886, 849, 764, 748, 696,671, 600cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.93(dd,J=6.8Hz,3JP-Se=20.5Hz,3H,PCHCH3中のCH3),1.22(dd,J=6.8Hz,3JP-Se=19.0Hz,3H,PCHCH3中のCH3),1.53(d,J=6.8Hz,3H,NCHCH3中のCH3), 2.22-2.33(m,1H,PCH),2.35(s,broad,1H,NH), 4.29-4.37(m,1H,NCH), 7.12-7.23(m,5H,Ar),7.26-7.31(m,2H,Ar), 7.37-7.41(m,1H,Ar), 7.74-7.80(m,2H,Ar).、 13C-NMR(CDCl3):δ16.5(PCHCH3中のCH3),25.5(d,3JC-P=4.1Hz,NCHCH3中のCH3),32.0(d,1JC-P=61.2Hz,PCH), 52.3(NCH), 126.3(Ar),127.0(Ar), 127.9(d,JC-P=12.4Hz,Ar), 128.3(Ar), 131.0(d,1JC-P=82.7Hz,Ar),131.5(d,4JC-P=3.3Hz,Ar), 132.5(d,JC-P=10.8Hz,Ar),144.7(d,JC-P= 5.8Hz,Ar).、 31P-NMR(CDCl3):δ75.0(1JP-Se=744.2Hz).、 77Se-NMR(CDCl3):δ-368.0(d,1JSe-P=744.2Hz).
<質量分析> MS (EI) m/z 351 (M+).(Compound 2a)
<Infrared absorption spectrum (KBr tablet)> 3248, 3058, 3022, 2969, 2927, 2869, 1493, 1466, 1454, 1435, 1418, 1383, 1365, 1314, 1294, 1277, 1254, 1208,1183, 1160, 1119, 1100, 1083, 1065, 1026, 997, 959, 910, 886, 833, 752, 697,674cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.86 (dd, J = 7.0 Hz, 3 J P-Se = 20.3 Hz, 3H, CH in PCHCH 3 3), 1.13 (dd, J = 6.8Hz, 3 J P-Se = 19.5Hz, 3H, CH 3 in PCHCH 3), 1.29 (d, J = 6.3Hz, 3H, CH 3 in NCHCH 3), 1.99 (s, broad, 1H, NH), 2.18-2.31 (m, 1H, PCH), 4.64-4.72 (m, 1H, NCH), 7.24-7.54 (m, 8H, Ar), 8.02-8.07 (m, . 2H, Ar), 13 C -NMR (CDCl 3): δ16.5 (PCHCH 3 CH 3 in), 16.6 (CH 3 in PCHCH 3), 24.8 (d, 3 J CP = 3.3Hz, NCHCH 3 CH 3 ), 32.6 (d, 1 J CP = 61.2Hz, PCH), 52.3 (NCH), 126.5 (Ar), 127.3 (Ar), 128.2 (d, J CP = 11.6Hz, Ar), 128.6 ( Ar), 131.7 (d, 4 J CP = 2.5Hz, Ar), 132.2 (d, J CP = 10.8Hz, Ar), 133.1 (Ar; One half of the signal isoverlapping with another signal), 145.0 (d, J CP = 7.4 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 74.1 ( 1 J P-Se = 745.6 Hz)., 77 Se-NMR (CDCl 3 ): δ-386.8 (d, 1 J (Se-P = 745.6Hz).
<Mass spectrometry> MS (EI) m / z 351 (M + ).
(Compound 2b)
<Infrared absorption spectrum (KBr tablet)> 3291, 3079, 3060, 3023, 2976,2927, 2881, 2871, 1491, 1452, 1438, 1412, 1387, 1365, 1308, 1298, 1278, 1243,1204, 1119, 1103, 1085, 1067, 1021, 999, 962, 929, 886, 849, 764, 748, 696,671, 600cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.93 (dd, J = 6.8 Hz, 3 J P-Se = 20.5 Hz, 3H, CH in PCHCH 3 3), 1.22 (dd, J = 6.8Hz, 3 J P-Se = 19.0Hz, 3H, CH 3 in PCHCH 3), 1.53 (d, J = 6.8Hz, 3H, CH 3 in NCHCH 3), 2.22-2.33 (m, 1H, PCH), 2.35 (s, broad, 1H, NH), 4.29-4.37 (m, 1H, NCH), 7.12-7.23 (m, 5H, Ar), 7.26-7.31 (m, . 2H, Ar), 7.37-7.41 ( m, 1H, Ar), 7.74-7.80 (m, 2H, Ar), 13 C-NMR (CDCl 3): δ16.5 (CH 3 in PCHCH 3), 25.5 (d, 3 J CP = 4.1Hz, CH 3 in NCHCH 3 ), 32.0 (d, 1 J CP = 61.2Hz, PCH), 52.3 (NCH), 126.3 (Ar), 127.0 (Ar), 127.9 (d , J CP = 12.4Hz, Ar), 128.3 (Ar), 131.0 (d, 1 J CP = 82.7Hz, Ar), 131.5 (d, 4 J CP = 3.3Hz, Ar), 132.5 (d, J CP = 10.8 Hz, Ar), 144.7 (d, J CP = 5.8 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 75.0 ( 1 J P-Se = 744.2 Hz)., 77 Se-NMR (CDCl 3 ): δ-368.0 (d, 1 J Se-P = 744.2Hz).
<Mass Spectrometry> MS (EI) m / z 351 (M + ).
以上の結果より、化合物2aは下記式(15)に示した構造を有しており、(RP,S)-P-1-メチルエチル-P-フェニル-N-1-フェニルエチルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は36%(収量:0.252g,0.72mmol)であり、融点は65〜67℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-44°であった。From the above results, compound 2a has the structure represented by the following formula (15), and (R P , S) -P-1-methylethyl-P-phenyl-N-1-phenylethylselenophosphinic acid Identified as an amide. The yield of this selenophosphinic acid amide is 36% (yield: 0.252 g, 0.72 mmol), the melting point is 65 to 67 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 44 °.
(化合物3a)
<赤外吸収スペクトル(KBr錠剤)> 3291, 3068, 3051, 3026, 2966,2925, 2852, 1493, 1450, 1436, 1410, 1371, 1341, 1310, 1297, 1269, 1201, 1176,1101, 1083, 1064, 1029, 1020, 1000, 956, 888, 853, 838, 822, 751, 737, 697,603cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.89-1.85(m,11H,CH2,CH),1.21(d,J=6.8Hz,3H,NCHCH3中のCH3), 2.25(s,broad,1H,NH),4.57-4.65(m,1H,NCH), 7.16-7.20(m,1H,Ar), 7.26(t,J=7.8Hz,2H,Ar),7.33-7.44(m,5H,Ar), 7.94-7.98(m,2H,Ar).、 13C-NMR(CDCl3):δ24.6(d,3JC-P=3.3Hz,NCHCH3中のCH3),25.5(CH2), 25.9(d,JC-P=14.9Hz,CH2), 26.0(d,JC-P=14.9Hz,CH2),26.1(CH2), 26.3(CH2), 42.4(d,1JC-P=59.5Hz,CH),52.0(NCH), 126.6(Ar), 127.3(Ar), 128.0(d,JC-P=12.4Hz,Ar), 128.5(Ar),131.6(d,4JC-P=2.5Hz,Ar), 132.3(d,JC-P=9.9Hz,Ar),132.6(d,1JC-P=81.9Hz,Ar), 145.0(d,JC-P=6.6Hz,Ar).、 31P-NMR(CDCl3):δ70.2(1JP-Se=739.6Hz).、 77Se-NMR(CDCl3):δ-363.5(d,1JSe-P=739.6Hz).
<質量分析> MS (EI) m/z 391 (M+).
(化合物3b)
<赤外吸収スペクトル(KBr錠剤)> 3263, 3060, 3049, 3029, 2980,2959, 2928, 2854, 1491, 1446, 1435, 1411, 1374, 1311, 1279, 1204, 1177, 1122,1102, 1086, 1032, 998, 960, 917, 889, 855, 834, 822, 755, 739, 695, 602cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.06-1.95(m,11H,CH2,CH),1.47(d,J=6.8Hz,3H,NCHCH3中のCH3), 2.37(s,broad,1H,NH),4.21-4.31(m,1H,NCH), 7.06-7.41(m,8H,Ar), 7.65-7.70(m,2H,Ar).、 13C-NMR(CDCl3):δ25.5(d,2JC-P=4.1Hz,NCHCH3中のCH3),25.6(CH2), 25.9(d,JC-P=15.7Hz,CH2), 26.0(CH2),26.0(d,JC-P=14.9Hz,CH2), 26.2(CH2), 42.1(d,1JC-P=60.4Hz,CH),52.1(NCH), 126.2(Ar), 126.9(Ar), 127.7(d,JC-P=12.4Hz,Ar), 128.3(Ar),130.5(Ar;One half of the signal is overlapping with another signal), 131.4(d,JC-P=2.5Hz,Ar),132.6(d,JC-P=10.8Hz,Ar), 144.7(d,JC-P=5.8Hz,Ar).、 31P-NMR(CDCl3):δ70.8(1JP-Se=739.6Hz).、 77Se-NMR(CDCl3):δ-342.9(d,1JSe-P=739.6Hz).
<質量分析> MS (EI) m/z 391 (M+).(Compound 3a)
<Infrared absorption spectrum (KBr tablet)> 3291, 3068, 3051, 3026, 2966,2925, 2852, 1493, 1450, 1436, 1410, 1371, 1341, 1310, 1297, 1269, 1201, 1176,1101, 1083, 1064, 1029, 1020, 1000, 956, 888, 853, 838, 822, 751, 737, 697,603cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.89-1.85 (m, 11 H, CH 2 , CH), 1.21 (d, J = 6.8 Hz, 3H, CH 3 in NCHCH 3), 2.25 (s, broad, 1H, NH), 4.57-4.65 (m, 1H, NCH), 7.16-7.20 (m, 1H, Ar), 7.26 (t, J = 7.8Hz, 2H, Ar), 7.33-7.44 (m, 5H, Ar), 7.94-7.98 (m, 2H, Ar)., 13 C-NMR (CDCl 3 ): δ24.6 (d, 3 J CP = 3.3 Hz, CH 3 in NCHCH 3 ), 25.5 (CH 2 ), 25.9 (d, J CP = 14.9Hz, CH 2 ), 26.0 (d, J CP = 14.9Hz, CH 2 ), 26.1 (CH 2 ), 26.3 ( CH 2 ), 42.4 (d, 1 J CP = 59.5Hz, CH), 52.0 (NCH), 126.6 (Ar), 127.3 (Ar), 128.0 (d, J CP = 12.4Hz, Ar), 128.5 (Ar) , 131.6 (d, 4 J CP = 2.5Hz, Ar), 132.3 (d, J CP = 9.9Hz, Ar), 132.6 (d, 1 J CP = 81.9Hz, Ar), 145.0 (d, J CP = 6.6 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 70.2 ( 1 J P-Se = 739.6 Hz). 77 Se-NMR (CDCl 3 ): δ-363.5 (d, 1 J Se-P = 739.6Hz).
<Mass Spectrometry> MS (EI) m / z 391 (M + ).
(Compound 3b)
<Infrared absorption spectrum (KBr tablet)> 3263, 3060, 3049, 3029, 2980, 2959, 2928, 2854, 1491, 1446, 1435, 1411, 1374, 1311, 1279, 1204, 1177, 1122,1102, 1086, 1032, 998, 960, 917, 889, 855, 834, 822, 755, 739, 695, 602cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.06-1.95 (m, 11H, CH 2 , CH), 1.47 (d, J = 6.8 Hz, 3H, CH 3 in NCHCH 3), 2.37 (s, broad, 1H, NH), 4.21-4.31 (m, 1H, NCH), 7.06-7.41 (m, 8H, Ar), 7.65-7.70 (m, 2H, Ar ), 13 C-NMR (CDCl 3):. δ25.5 (d, 2 J CP = 4.1Hz, CH 3 in NCHCH 3), 25.6 (CH 2 ), 25.9 (d, J CP = 15.7Hz, CH 2 ), 26.0 (CH 2 ), 26.0 (d, J CP = 14.9Hz, CH 2 ), 26.2 (CH 2 ), 42.1 (d, 1 J CP = 60.4Hz, CH), 52.1 (NCH), 126.2 ( Ar), 126.9 (Ar), 127.7 (d, J CP = 12.4Hz, Ar), 128.3 (Ar), 130.5 (Ar; One half of the signal is overlapping with another signal), 131.4 (d, J CP = 2.5 . Hz, Ar), 132.6 ( d, J CP = 10.8Hz, Ar), 144.7 (d, J CP = 5.8Hz, Ar), 31 P-NMR (CDCl 3): δ70.8 (1 J P-Se = 739.6 Hz)., 77 Se-NMR (CDCl 3 ): δ-342.9 (d, 1 J Se-P = 739.6 Hz).
<Mass Spectrometry> MS (EI) m / z 391 (M + ).
以上の結果より、化合物3aは下記式(17)に示した構造を有しており、(RP,S)-P-シクロヘキシル-P-フェニル-N-1-フェニルエチルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は37%(収量:0.286g,0.73mmol)であり、融点は75〜77℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-40°であった。From the above results, compound 3a has the structure represented by the following formula (17), and is (R P , S) -P- cyclohexyl- P -phenyl-N-1-phenylethylselenophosphinic acid amide. Was identified. The yield of this selenophosphinic acid amide is 37% (yield: 0.286 g, 0.73 mmol), the melting point is 75-77 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 40 °.
(化合物4a)
<赤外吸収スペクトル(KBr錠剤)> 3334, 3276, 3048, 2968, 2946,2924, 2900, 2865, 1596, 1508, 1472, 1456, 1433, 1390, 1370, 1362, 1326, 1277,1233, 1190, 1170, 1119, 1106, 1098, 1081, 1030, 1016, 999, 969, 947, 939, 856,827, 797, 774, 752, 745, 721, 700, 645, 627, 609cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.06(d,3JH-P=17.1Hz,9H,CCH3),1.40(d,J=6.8Hz,3H,CHCH3中のCH3), 2.50(s,broad,1H,NH),5.61-5.69(m,1H,CHCH3中のCH), 7.48-7.59(m,6H,Ar),7.68(d,J=6.8Hz,1H,Ar), 7.81(d,J=8.3Hz,1H,Ar), 7.87(d,J=8.3Hz,1H,Ar),8.08-8.13(m,2H,Ar), 8.46(d,J=8.3Hz,1H,Ar).、 13C-NMR(CDCl3):δ23.1(CHCH3中のCH3),24.9(CCH3中のCH3), 35.7(d,1JC-P=56.2Hz,CCH3においてCH3に結合するC),48.6(CHCH3中のCH), 123.2(Ar), 124.3(Ar), 125.3(Ar), 125.9(Ar),126.5(Ar), 127.6(d,JC-P=11.6Hz,Ar), 128.2(Ar), 128.7(Ar), 130.7(Ar),131.5(d,4JC-P=2.5Hz,Ar), 132.7(d,1JC-P=78.6Hz,Ar),133.2(d,JC-P=9.9Hz,Ar), 134.0(Ar), 140.4(d,JC-P=9.1Hz,Ar).、 31P-NMR(CDCl3):δ78.3(1JP-Se=745.6Hz).、 77Se-NMR(CDCl3):δ-388.5(d,1JSe-P=745.6Hz).
<質量分析> MS (EI) m/z 415 (M+).
<元素分析> Anal. Calcd for C22H26NPSe(414.38):C,63.77;H,6.32;N,7.47. Found:C,63.50;H,6.30;N,3.35.
(化合物4b)
<赤外吸収スペクトル(KBr錠剤)> 3384, 3050, 2968, 2956, 2922,2898, 2864, 1596, 1509, 1472, 1459, 1433, 1368, 1360, 1331, 1308, 1270, 1253,1236, 1191, 1167, 1098, 1076, 1022, 998, 948, 848, 832, 801, 781, 746, 718,692, 645, 627, 606cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.22(d,3JH-P=17.0Hz,9H,CCH3),1.74(d,J=6.8Hz,3H,CHCH3中のCH3), 2.49(s,broad,1H,NH),5.19-5.30(m,1H,CHCH3中のCH), 7.03(dt,J=3.4,7.8Hz,2H,Ar),7.18-7.27(m,2H,Ar), 7.37(t,J=7.3Hz,1H,Ar), 7.48(t,J=7.8Hz,1H,Ar),7.63-7.83(m,6H,Ar).、 13C-NMR(CDCl3):δ25.0(d,2JC-P=1.7Hz,CCH3中のCH3),26.1(d,3JC-P=1.7Hz,CHCH3中のCH3),35.3(d,1JC-P=56.2Hz,CCH3においてCH3に結合するC),48.7(CHCH3中のCH), 122.7(Ar), 123.3(Ar), 125.3(Ar), 125.5(Ar),125.8(Ar), 127.2(d,JC-P=12.4Hz,Ar), 127.5(Ar), 128.5(Ar), 129.9(Ar),130.2(d,1JC-P=81.9Hz,Ar), 131.2(d,4JC-P=2.5Hz,Ar),133.5(d,JC-P=10.8Hz,Ar), 133.7(Ar), 141.3(d,JC-P=5.8Hz,Ar).、 31P-NMR(CDCl3):δ82.0(1JP-Se=744.2Hz).、 77Se-NMR(CDCl3):δ-336.9(d,1JSe-P=744.2Hz).
<質量分析> MS (EI) m/z 415 (M+).
<元素分析> Anal. Calcd for C22H26NPSe(414.38):C,63.77;H,6.32;N,7.47. Found:C,63.50;H,6.30;N,3.35.(Compound 4a)
<Infrared absorption spectrum (KBr tablet)> 3334, 3276, 3048, 2968, 2946, 2924, 2900, 2865, 1596, 1508, 1472, 1456, 1433, 1390, 1370, 1362, 1326, 1277,1233, 1190, 1170, 1119, 1106, 1098, 1081, 1030, 1016, 999, 969, 947, 939, 856,827, 797, 774, 752, 745, 721, 700, 645, 627, 609cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.06 (d, 3 J HP = 17.1 Hz, 9 H, CCH 3 ), 1.40 (d, J = 6.8 Hz , 3H, CH 3 in CHCH 3), 2.50 (s, broad, 1H, NH), 5.61-5.69 (m, 1H, CH in CHCH 3), 7.48-7.59 (m, 6H, Ar), 7.68 ( d, J = 6.8Hz, 1H, Ar), 7.81 (d, J = 8.3Hz, 1H, Ar), 7.87 (d, J = 8.3Hz, 1H, Ar), 8.08-8.13 (m, 2H, Ar) , 8.46 (d, J = 8.3Hz , 1H, Ar), 13 C-NMR (CDCl 3):. δ23.1 (CH 3 in CHCH 3), (CH 3 in CCH 3) 24.9, 35.7 (d , 1 J CP = 56.2Hz, C binding to CH 3 in CCH 3 ), 48.6 (CH in CHCH 3 ), 123.2 (Ar), 124.3 (Ar), 125.3 (Ar), 125.9 (Ar), 126.5 ( Ar), 127.6 (d, J CP = 11.6Hz, Ar), 128.2 (Ar), 128.7 (Ar), 130.7 (Ar), 131.5 (d, 4 J CP = 2.5Hz, Ar), 132.7 (d, 1 J CP = 78.6 Hz, Ar), 133.2 (d, J CP = 9.9 Hz, Ar), 134.0 (Ar), 140.4 (d, J CP = 9.1 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 78.3 ( 1 J P-Se = 745.6 Hz). 77 Se-NMR (CDCl 3 ): δ-388.5 (d, 1 J Se-P = 745.6 Hz).
<Mass spectrometry> MS (EI) m / z 415 (M + ).
<Elemental analysis> Anal. Calcd for C 22 H 26 NPSe (414.38): C, 63.77; H, 6.32; N, 7.47. Found: C, 63.50; H, 6.30; N, 3.35.
(Compound 4b)
<Infrared absorption spectrum (KBr tablet)> 3384, 3050, 2968, 2956, 2922, 2898, 2864, 1596, 1509, 1472, 1459, 1433, 1368, 1360, 1331, 1308, 1270, 1253,1236, 1191, 1167, 1098, 1076, 1022, 998, 948, 848, 832, 801, 781, 746, 718,692, 645, 627, 606cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.22 (d, 3 J HP = 17.0 Hz, 9 H, CCH 3 ), 1.74 (d, J = 6.8 Hz , 3H, CH 3 in CHCH 3), 2.49 (s, broad, 1H, NH), 5.19-5.30 (m, 1H, CH in CHCH 3), 7.03 (dt, J = 3.4,7.8Hz, 2H, Ar), 7.18-7.27 (m, 2H, Ar), 7.37 (t, J = 7.3Hz, 1H, Ar), 7.48 (t, J = 7.8Hz, 1H, Ar), 7.63-7.83 (m, 6H, . Ar), 13 C-NMR (CDCl 3): δ25.0 (d, 2 J CP = 1.7Hz, CH 3 in CCH 3), 26.1 (d, 3 J CP = 1.7Hz, CH in CHCH 3 3 ), 35.3 (d, 1 J CP = 56.2Hz, C bonded to CH 3 in CCH 3 ), 48.7 (CH in CHCH 3 ), 122.7 (Ar), 123.3 (Ar), 125.3 (Ar), 125.5 (Ar), 125.8 (Ar), 127.2 (d, J CP = 12.4Hz, Ar), 127.5 (Ar), 128.5 (Ar), 129.9 (Ar), 130.2 (d, 1 J CP = 81.9Hz, Ar) , 131.2 (d, 4 J CP = 2.5Hz, Ar), 133.5 (d, J CP = 10.8Hz, Ar), 133.7 (Ar), 141.3 (d, J CP = 5.8Hz, Ar)., 31 P- NMR (CDCl 3 ): δ 82.0 ( 1 J P-Se = 744.2 Hz). 77 Se-NMR (CDCl 3 ): δ-336.9 (d, 1 J Se-P = 744.2 Hz).
<Mass spectrometry> MS (EI) m / z 415 (M + ).
<Elemental analysis> Anal. Calcd for C 22 H 26 NPSe (414.38): C, 63.77; H, 6.32; N, 7.47. Found: C, 63.50; H, 6.30; N, 3.35.
以上の結果より、化合物4aは下記式(19)に示した構造を有しており、(RP,S)-P-1,1-ジメチルエチル-N-1-(1-ナフチル)エチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は36%(収量:0.296g,0.71mmol)、融点は155〜157℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-13°であった。From the above results, compound 4a has the structure represented by the following formula (19), and (R P , S) -P-1,1-dimethylethyl-N-1- (1-naphthyl) ethyl- It was identified as P-phenylselenophosphinic acid amide. The yield of this selenophosphinic acid amide is 36% (yield: 0.296 g, 0.71 mmol), the melting point is 155-157 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is −13 °. Met.
(化合物5a)
<赤外吸収スペクトル(KBr錠剤)> 3243, 3046, 2979, 2962, 2928,2871, 1680, 1598, 1508, 1463, 1449, 1434, 1397, 1372, 1331, 1305, 1278, 1242,1171, 1115, 1098, 1081, 1031, 1022, 1001, 948, 883, 848, 824, 798, 779, 743,721, 705, 690, 675, 645, 612cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.82(dd,J=6.8Hz,3JP-Se=20.0Hz,3H,PCHCH3中のCH3),1.07(dd,J=6.8Hz,3JP-Se=19.0Hz,3H,PCHCH3中のCH3),1.37(d,J=6.3Hz,3H,NCHCH3中のCH3), 2.12-2.25(m,1H,PCH),2.55(s,broad,1H,NH), 5.49-5.58(m,1H,NCH), 7.43-7.62(m,7H,Ar),7.77(d,J=8.3Hz,1H,Ar), 7.85(d,J=7.8Hz,1H,Ar), 8.03-8.09(m,2H,Ar),8.38(d,J=8.3Hz,1H,Ar).、 13C-NMR(CDCl3):δ16.4(PCHCH3中のCH3),16.5(PCHCH3中のCH3), 23.5(NCHCH3中のCH3),32.5(d,1JC-P=61.2Hz,PCH), 48.2(NCH), 123.2(Ar),123.9(Ar), 125.3(Ar), 125.8(Ar), 126.4(Ar), 128.1(Ar), 128.1(d,JC-P=12.4Hz,Ar),128.7(Ar), 130.5(Ar), 131.6(d,4JC-P=2.5Hz,Ar), 131.9(d,JC-P=10.8Hz,Ar),133.4(d,1JC-P=80.2Hz,Ar), 133.9(Ar), 140.3(d,JC-P=8.3Hz,Ar).、 31P-NMR(CDCl3):δ73.8(1JP-Se=745.6Hz).、 77Se-NMR(CDCl3):δ-414.3(d,1JSe-P=745.6Hz).
<質量分析> MS (EI) m/z 401 (M+).
(化合物5b)
<赤外吸収スペクトル(KBr錠剤)> 3307, 3061, 3047, 2976, 2959,2928, 2871, 1597, 1510, 1464, 1447, 1437, 1385, 1363, 1310, 1282, 1241, 1173,1121, 1102, 1076, 1027, 1015, 951, 883, 860, 828, 795, 777, 754, 721, 705, 696,667, 617cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.95(dd,J=6.8Hz,3JP-Se=20.0Hz,3H,PCHCH3中のCH3),1.26(dd,J=6.8Hz,3JP-Se=19.0Hz,3H,PCHCH3中のCH3),1.67(d,J=6.3Hz,3H,NCHCH3中のCH3), 2.25-2.38(m,1H,PCH),2.57(s,broad,1H,NH), 5.10-5.21(m,1H,NCH), 7.10-7.15(m,2H,Ar),7.23-7.28(m,1H,Ar), 7.29-7.34(m,1H,Ar), 7.37-7.42(m,2H,Ar),7.55(d,J=6.9Hz,1H,Ar), 7.67-7.72(m,3H,Ar), 7.77-7.84(m,2H,Ar).、 13C-NMR(CDCl3):δ16.5(PCHCH3中のCH3),16.6(PCHCH3中のCH3), 25.9(d,3JC-P=3.3Hz,NCHCH3中のCH3),32.2(d,1JC-P=61.2Hz,PCH), 48.7(NCH), 123.1(Ar),123.2(Ar), 125.3(Ar), 125.5(Ar), 125.8(Ar), 127.6(Ar), 127.8(d,JC-P=12.4Hz,Ar),128.7(Ar), 130.0(Ar), 130.9(d,1JC-P=82.7Hz,Ar), 131.4(d,4JC-P=2.5Hz,Ar),132.3(d,JC-P=10.8Hz,Ar), 133.7(Ar), 140.9(d,JC-P=5.0Hz,Ar).、 31P-NMR(CDCl3):δ75.5(1JP-Se=744.2Hz).、 77Se-NMR(CDCl3):δ-371.2(d,1JSe-P=744.2Hz).
<質量分析> MS (EI) m/z 401 (M+).(Compound 5a)
<Infrared absorption spectrum (KBr tablet)> 3243, 3046, 2979, 2962, 2928,2871, 1680, 1598, 1508, 1463, 1449, 1434, 1397, 1372, 1331, 1305, 1278, 1242,1171, 1115, 1098, 1081, 1031, 1022, 1001, 948, 883, 848, 824, 798, 779, 743,721, 705, 690, 675, 645, 612cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.82 (dd, J = 6.8 Hz, 3 J P-Se = 20.0 Hz, 3H, CH in PCHCH 3 3), 1.07 (dd, J = 6.8Hz, 3 J P-Se = 19.0Hz, 3H, CH 3 in PCHCH 3), 1.37 (d, J = 6.3Hz, 3H, CH 3 in NCHCH 3), 2.12-2.25 (m, 1H, PCH), 2.55 (s, broad, 1H, NH), 5.49-5.58 (m, 1H, NCH), 7.43-7.62 (m, 7H, Ar), 7.77 (d, J = 8.3Hz, 1H, Ar), 7.85 (d, J = 7.8Hz, 1H, Ar), 8.03-8.09 (m, 2H, Ar), 8.38 (d, J = 8.3Hz, 1H, Ar), 13 C -NMR (CDCl 3): δ16.4 ( CH 3 in PCHCH 3), 16.5 (CH 3 in PCHCH 3), 23.5 (CH 3 in NCHCH 3), 32.5 (d, 1 J CP = 61.2Hz, PCH), 48.2 (NCH), 123.2 (Ar), 123.9 (Ar), 125.3 (Ar), 125.8 (Ar), 126.4 (Ar), 128.1 (Ar), 128.1 (d, J CP = 12.4Hz, Ar) , 128.7 (Ar), 130.5 (Ar), 131.6 (d, 4 J CP = 2.5Hz, Ar), 131.9 (d, J CP = 10.8Hz, Ar), 133.4 (d, 1 J CP = 80.2Hz, Ar ), 133.9 (Ar), 140.3 (d, J CP = 8.3 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ73.8 ( 1 J P-Se = 745.6 Hz)., 77 Se-NMR ( CDCl 3 ): δ-414.3 (d, 1 J Se-P = 745.6 Hz).
<Mass Spectrometry> MS (EI) m / z 401 (M + ).
(Compound 5b)
<Infrared absorption spectrum (KBr tablet)> 3307, 3061, 3047, 2976, 2959, 2928, 2871, 1597, 1510, 1464, 1447, 1437, 1385, 1363, 1310, 1282, 1241, 1173,1121, 1102, 1076, 1027, 1015, 951, 883, 860, 828, 795, 777, 754, 721, 705, 696,667, 617cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.95 (dd, J = 6.8 Hz, 3 J P-Se = 20.0 Hz, 3H, CH in PCHCH 3 3), 1.26 (dd, J = 6.8Hz, 3 J P-Se = 19.0Hz, 3H, CH 3 in PCHCH 3), 1.67 (d, J = 6.3Hz, 3H, CH 3 in NCHCH 3), 2.25-2.38 (m, 1H, PCH), 2.57 (s, broad, 1H, NH), 5.10-5.21 (m, 1H, NCH), 7.10-7.15 (m, 2H, Ar), 7.23-7.28 (m, 1H, Ar), 7.29-7.34 (m, 1H, Ar), 7.37-7.42 (m, 2H, Ar), 7.55 (d, J = 6.9Hz, 1H, Ar), 7.67-7.72 (m, 3H, Ar .), 7.77-7.84 (m, 2H , Ar), 13 C-NMR (CDCl 3): δ16.5 (CH 3 in PCHCH 3), 16.6 (CH 3 in PCHCH 3), 25.9 (d, 3 J CP = 3.3Hz, CH 3 in NCHCH 3 ), 32.2 (d, 1 J CP = 61.2Hz, PCH), 48.7 (NCH), 123.1 (Ar), 123.2 (Ar), 125.3 (Ar), 125.5 ( Ar), 125.8 (Ar), 127.6 (Ar), 127.8 (d, J CP = 12.4Hz, Ar), 128.7 (Ar), 130.0 (Ar), 130.9 (d, 1 J CP = 82.7Hz, Ar), 131.4 (d, 4 J CP = 2.5Hz, Ar), 132.3 (d, J CP = 10.8Hz, Ar), 133.7 (Ar), 140.9 (d, J CP = 5.0Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 75.5 ( 1 J P-Se = 744.2 Hz). 77 Se-NMR (CDCl 3 ): δ-371.2 (d, 1 J Se-P = 744.2 Hz).
<Mass Spectrometry> MS (EI) m / z 401 (M + ).
以上の結果より、化合物5aは下記式(21)に示した構造を有しており、(RP,S)-P-1-メチルエチル-N-1-(1-ナフチル)エチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は38%(収量:0.301g,0.76mmol)であり、融点は109〜111℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-28°であった。From the above results, compound 5a has the structure represented by the following formula (21), and (R P , S) -P-1-methylethyl-N-1- (1-naphthyl) ethyl-P— It was identified as phenylselenophosphinic acid amide. The yield of this selenophosphinic acid amide is 38% (yield: 0.301 g, 0.76 mmol), the melting point is 109-111 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 28 °.
(化合物6a)
<赤外吸収スペクトル(KBr錠剤)> 3049, 2928, 2851, 1597, 1510,1435, 1371, 1173, 1098, 1021, 1000, 949, 888, 853, 827, 798, 776, 740, 692,647, 635, 612cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.92-1.94(m,11H,CH2,CH),1.37(d,J=6.3Hz,3H,NCHCH3中のCH3), 2.52(s,broad,1H,NH),5.49-5.58(m,1H,NCH), 7.45-7.60(m,6H,Ar), 7.63(d,J=7.3Hz,1H,Ar),7.79(d,J=8.3Hz,1H,Ar), 7.87(d,J=7.3Hz,1H,Ar), 8.04-8.09(m,2H,Ar),8.41(d,J=8.8Hz,1H,Ar).、 13C-NMR(CDCl3):δ23.5(NCHCH3中のCH3),25.5(CH2), 25.9(d,JC-P=14.9Hz,CH2), 25.9(CH2),26.0(d,JC-P=15.7Hz,CH2), 26.2(CH2), 42.4(d,1JC-P=60.4Hz,CH),48.2(NCH), 123.4(Ar), 123.9(Ar), 125.3(Ar), 125.9(Ar), 126.4(Ar), 128.1(d,JC-P=12.4Hz,Ar),128.2(Ar), 128.7(Ar), 130.6(Ar), 131.6(d,4JC-P=2.5Hz,Ar),132.2(d,JC-P=9.9Hz,Ar), 133.4(d,1JC-P=81.9Hz,Ar),134.0(Ar), 140.4(d,JC-P=8.3Hz,Ar).、 31P-NMR(CDCl3):δ69.8(1JP-Se=744.2Hz).、 77Se-NMR(CDCl3):δ-390.6(d,1JSe-P=744.2Hz).
<質量分析> MS (EI) m/z 441 (M+).
(化合物6b)
<赤外吸収スペクトル(KBr錠剤)> 3297, 3049, 2926, 2851, 1597,1510, 1436, 1369, 1308, 1255, 1235, 1172, 1100, 1075, 1021, 1000, 945, 887,851, 824, 797, 776, 740, 691, 648, 619cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.10-1.70(m,8H,CH2),1.68(d,J=6.7Hz,3H,NCHCH3中のCH3), 1.83-1.86(m,1H,CH2),1.99-2.07(m,2H,CH2,CH), 2.59(s,broad,1H,NH), 5.12-5.22(m,1H,NCH),7.04-7.11(m,2H,Ar), 7.20-7.42(m,4H,Ar), 7.56(d,J=7.3Hz,1H,Ar),7.68(dt,J=2.9,7.3Hz,3H,Ar), 7.77(d,J=7.8Hz,1H,Ar), 7.83(d,J=8.3Hz,1H,Ar).、 13C-NMR(CDCl3):δ25.6(CH3),25.8(CH2), 25.88(d,JC-P=12.4Hz,CH2), 25.92(d,JC-P=12.4Hz,CH2),26.0(CH2), 26.3(CH2), 42.3(d,1JC-P=60.4Hz,CH),48.4(NCH), 123.1(Ar), 123.2(Ar), 125.2(Ar), 125.4(Ar), 125.8(Ar), 127.5(Ar),127.6(d,JC-P=12.4Hz,Ar), 128.6(Ar), 129.9(Ar), 130.2(Ar;One half ofthe signal is overlapping with another signal), 131.2(Ar), 132.4(d,JC-P=10.8Hz,Ar),133.6(Ar), 140.9(d,JC-P=5.0Hz,Ar).、 31P-NMR(CDCl3):δ71.4(1JP-Se=738.1Hz).、 77Se-NMR(CDCl3):δ-346.3(d,1JSe-P=738.1Hz).
<質量分析> MS (EI) m/z 441 (M+).(Compound 6a)
<Infrared absorption spectrum (KBr tablet)> 3049, 2928, 2851, 1597, 1510,1435, 1371, 1173, 1098, 1021, 1000, 949, 888, 853, 827, 798, 776, 740, 692,647, 635, 612cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ0.92-1.94 (m, 11H, CH 2 , CH), 1.37 (d, J = 6.3 Hz, 3H, CH 3 in NCHCH 3 ), 2.52 (s, broad, 1H, NH), 5.49-5.58 (m, 1H, NCH), 7.45-7.60 (m, 6H, Ar), 7.63 (d, J = 7.3Hz, 1H, Ar), 7.79 (d, J = 8.3Hz, 1H, Ar), 7.87 (d, J = 7.3Hz, 1H, Ar), 8.04-8.09 (m, 2H, Ar), 8.41 (d, J = . 8.8Hz, 1H, Ar), 13 C-NMR (CDCl 3): δ23.5 (CH 3 in NCHCH 3), 25.5 (CH 2 ), 25.9 (d, J CP = 14.9Hz, CH 2), 25.9 (CH 2 ), 26.0 (d, J CP = 15.7 Hz, CH 2 ), 26.2 (CH 2 ), 42.4 (d, 1 J CP = 60.4 Hz, CH), 48.2 (NCH), 123.4 (Ar), 123.9 (Ar), 125.3 (Ar), 125.9 (Ar), 126.4 (Ar), 128.1 (d, J CP = 12.4Hz, Ar), 128.2 (Ar), 128.7 (Ar), 130.6 (Ar), 131.6 ( d, 4 J CP = 2.5Hz, Ar), 132.2 (d, J CP = 9.9Hz, Ar), 133.4 (d, 1 J CP = 81.9Hz, Ar), 134.0 (Ar), 140.4 (d, J CP = 8.3 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 69.8 ( 1 J P-Se = 744.2 Hz)., 77 Se-NMR (CDCl 3 ): δ-390.6 (d, 1 J Se -P = 744.2Hz).
<Mass spectrometry> MS (EI) m / z 441 (M + ).
(Compound 6b)
<Infrared absorption spectrum (KBr tablet)> 3297, 3049, 2926, 2851, 1597, 1510, 1436, 1369, 1308, 1255, 1235, 1172, 1100, 1075, 1021, 1000, 945, 887,851, 824, 797, 776, 740, 691, 648, 619cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.10-1.70 (m, 8H, CH 2 ), 1.68 (d, J = 6.7Hz, 3H, NCHCH 3 CH 3 ), 1.83-1.86 (m, 1H, CH 2 ), 1.99-2.07 (m, 2H, CH 2 , CH), 2.59 (s, broad, 1H, NH), 5.12-5.22 (m, 1H , NCH), 7.04-7.11 (m, 2H, Ar), 7.20-7.42 (m, 4H, Ar), 7.56 (d, J = 7.3Hz, 1H, Ar), 7.68 (dt, J = 2.9,7.3Hz , 3H, Ar), 7.77 (d, J = 7.8 Hz, 1H, Ar), 7.83 (d, J = 8.3 Hz, 1H, Ar)., 13 C-NMR (CDCl 3 ): δ25.6 (CH 3 ), 25.8 (CH 2 ), 25.88 (d, J CP = 12.4Hz, CH 2 ), 25.92 (d, J CP = 12.4Hz, CH 2 ), 26.0 (CH 2 ), 26.3 (CH 2 ), 42.3 ( d, 1 J CP = 60.4Hz, CH), 48.4 (NCH), 123.1 (Ar), 123.2 (Ar), 125.2 (Ar), 125.4 (Ar), 125.8 (Ar), 127.5 (Ar), 127.6 (d , J CP = 12.4Hz, Ar), 128.6 (Ar), 129.9 (Ar), 130.2 (Ar; One half of the signal is overlapping with another signal), 131.2 (Ar), 132.4 (d, J CP = 10.8Hz, Ar), 133.6 (Ar), 140.9 (d, J CP = 5.0 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ71.4 ( 1 J P-Se = 738.1 Hz)., 77 Se-NMR (CDCl 3 ): δ-346.3 (d, 1 J Se-P = 738.1 Hz).
<Mass spectrometry> MS (EI) m / z 441 (M + ).
以上の結果より、化合物6aは下記式(23)に示した構造を有しており、(RP,S)-P-シクロヘキシル-N-1-(1-ナフチル)エチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は34%(収量:0.298g,0.68mmol)であり、融点は52〜54℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-13°であった。From the above results, compound 6a has the structure shown in the following formula (23), and (R P , S) -P -cyclohexyl-N-1- (1-naphthyl) ethyl- P -phenylselenophosphine Identified as acid amide. The yield of this selenophosphinic acid amide is 34% (yield: 0.298 g, 0.68 mmol), the melting point is 52-54 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 13 °.
(化合物7a)
<赤外吸収スペクトル(KBr錠剤)> 3311, 2965, 2923, 2851, 1474,1465, 1447, 1434, 1404, 1389, 1376, 1362, 1310, 1275, 1187, 1130, 1099, 1073,1046, 1016, 997, 969, 943, 911, 890, 847, 826, 813, 747, 696, 629, 607cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.90(d,J=6.3Hz,3H,NCHCH3中のCH3),0.97-1.29(m,5H,CH2), 1.11(d,3J=16.6Hz,9H,CCH3),1.53-1.73(m,6H,CH2,CH), 2.18(s,broad,1H,NH), 3.37-3.48(m,1H,NCH),7.35-7.42(m,3H,Ar), 7.90-7.94(m,2H,Ar).、 13C-NMR(CDCl3):δ19.1(d,3JC-P=1.7Hz,CHCH3中のCH3),24.9(d,JC-P=1.6Hz,CCH3中のCH3), 26.26(CH2),26.34(CH2), 26.5(CH2), 28.0(CH2), 29.5(CH2),35.2(d,1JC-P=57.9Hz,CCH3においてCH3に結合するC),44.3(d,JC-P=6.6Hz,CH), 52.7(d,2JC-P=2.5Hz,NCH),127.4(d,JC-P=12.4Hz,Ar), 131.1(d,4JC-P=2.5Hz,Ar),132.4(Ar;One half of the signal is overlapping with another signal), 133.2(d,JC-P=10.8Hz,Ar).、 31P-NMR(CDCl3):δ77.4(1JP-Se=745.6Hz).、 77Se-NMR(CDCl3):δ-367.0(d,1JSe-P=745.6Hz).
<質量分析> MS (EI) m/z 371 (M+).
(化合物7b)
<赤外吸収スペクトル(KBr錠剤)> 3353, 3076, 3055, 2970, 2922,2850, 1638, 1572, 1473, 1447, 1436, 1410, 1391, 1378, 1362, 1308, 1292, 1186,1155, 1140, 1101, 1085, 1072, 1060, 1011, 967, 908, 892, 873, 846, 831, 811,752, 699, 636, 607cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.87-1.34(m,5H,CH2),1.13(d,3J=17.1Hz,9H,CCH3), 1.18(d,J=6.8Hz,3H,NCHCH3中のCH3),1.54-1.91(m,7H,CH2,CH,NH), 3.32-3.39(m,1H,NCH), 7.38-7.47(m,3H,Ar),7.95-8.01(m,2H,Ar).、 13C-NMR(CDCl3):δ18.5(d,3JC-P=3.3Hz,CHCH3中のCH3),24.9(CCH3中のCH3), 26.2(CH2), 26.3(CH2),26.4(CH2), 27.2(CH2), 29.7(CH2), 35.2(d,1JC-P=57.1Hz,CCH3においてCH3に結合するC),44.2(d,JC-P=5.0Hz,CH), 52.9(d,2JC-P=1.7Hz,NCH),127.3(d,JC-P=11.6Hz,Ar), 131.2(d,4JC-P=2.5Hz,Ar),131.6(d,1JC-P=81.1Hz,Ar), 133.3(d,JC-P=9.9Hz,Ar).、 31P-NMR(CDCl3):δ78.4(1JP-Se=741.1Hz).、 77Se-NMR(CDCl3):δ-353.6(d,1JSe-P=741.1Hz).
<質量分析> MS (EI) m/z 371 (M+).
以上の結果より、化合物7aは下記式(25)に示した構造を有しており、(RP,S)-N-1-シクロヘキシルエチル-P-1,1-ジメチルエチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は42%(収量:0.309g,0.83mmol)であり、融点は106〜108℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-32°であった。(Compound 7a)
<Infrared absorption spectrum (KBr tablet)> 3311, 2965, 2923, 2851, 1474,1465, 1447, 1434, 1404, 1389, 1376, 1362, 1310, 1275, 1187, 1130, 1099, 1073,1046, 1016, 997, 969, 943, 911, 890, 847, 826, 813, 747, 696, 629, 607cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.90 (d, J = 6.3Hz, 3H, CH 3 in NCHCH 3), 0.97-1.29 (m, 5H, CH 2 ), 1.11 (d, 3 J = 16.6Hz, 9H, CCH 3 ), 1.53-1.73 (m, 6H, CH 2 , CH), 2.18 (s, broad, 1H, NH), 3.37-3.48 (m, 1H, NCH), 7.35-7.42 (m, 3H, Ar), 7.90-7.94 (m, 2H, Ar)., 13 C-NMR (CDCl 3 ): δ 19.1 (d, 3 J CP = 1.7 Hz, CH 3 in CHCH 3), 24.9 (d, J CP = 1.6Hz, CH 3 in CCH 3), 26.26 (CH 2 ), 26.34 (CH 2), 26.5 (CH 2), 28.0 (CH 2 ), 29.5 (CH 2 ), 35.2 (d, 1 J CP = 57.9 Hz, C coupled to CH 3 in CCH 3 ), 44.3 (d, J CP = 6.6 Hz, CH), 52.7 (d, 2 J CP = 2.5Hz, NCH), 127.4 (d, J CP = 12.4Hz, Ar), 131.1 (d, 4 J CP = 2.5Hz, Ar), 132.4 (Ar; One half of the signal is overlapping with another signal) , 133.2 (d, J CP = 10.8 Hz, Ar). 31 P-NMR (CDCl 3 ): δ 77.4 ( 1 J P-Se = 745.6 Hz). 77 Se-NMR (CDCl 3 ): δ- 367.0 (d, 1 J Se-P = 745.6Hz).
<Mass Spectrometry> MS (EI) m / z 371 (M + ).
(Compound 7b)
<Infrared absorption spectrum (KBr tablet)> 3353, 3076, 3055, 2970, 2922,2850, 1638, 1572, 1473, 1447, 1436, 1410, 1391, 1378, 1362, 1308, 1292, 1186,1155, 1140, 1101, 1085, 1072, 1060, 1011, 967, 908, 892, 873, 846, 831, 811,752, 699, 636, 607cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ0.87-1.34 (m, 5H, CH 2 ), 1.13 (d, 3 J = 17.1Hz, 9H, CCH 3), 1.18 (d, J = 6.8Hz, 3H, CH 3 in NCHCH 3), 1.54-1.91 (m, 7H, CH 2, CH, NH), 3.32-3.39 (m, 1H, NCH), 7.38 . -7.47 (m, 3H, Ar ), 7.95-8.01 (m, 2H, Ar), 13 C-NMR (CDCl 3): δ18.5 (d, 3 J CP = 3.3Hz, CH 3 in CHCH 3 ), 24.9 (CH 3 in CCH 3 ), 26.2 (CH 2 ), 26.3 (CH 2 ), 26.4 (CH 2 ), 27.2 (CH 2 ), 29.7 (CH 2 ), 35.2 (d, 1 J CP = 57.1Hz, C bonded to CH 3 in CCH 3 ), 44.2 (d, J CP = 5.0Hz, CH), 52.9 (d, 2 J CP = 1.7Hz, NCH), 127.3 (d, J CP = 11.6Hz , Ar), 131.2 (d, 4 J CP = 2.5 Hz, Ar), 131.6 (d, 1 J CP = 81.1 Hz, Ar), 133.3 (d, J CP = 9.9 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 78.4 ( 1 J P-Se = 741.1 Hz). 77 Se-NMR (CDCl 3 ): δ-353.6 (d, 1 J Se-P = 741.1 Hz).
<Mass Spectrometry> MS (EI) m / z 371 (M + ).
From the above results, Compound 7a has the structure shown in the following formula (25), and (R P , S) -N-1-cyclohexylethyl-P-1,1-dimethylethyl-P-phenylseleno Identified as phosphinic acid amide. The yield of this selenophosphinic acid amide is 42% (yield: 0.309 g, 0.83 mmol), the melting point is 106-108 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 32 °.
(化合物8a)
<赤外吸収スペクトル(KBr錠剤)> 3298, 3262, 3069, 3050, 2968,2921, 2871, 2851, 1573, 1476, 1463, 1446, 1433, 1410, 1379, 1351, 1308, 1285,1258, 1238, 1189, 1154, 1097, 1073, 1049, 1037, 1028, 1013, 967, 930, 913, 887,873, 843, 824, 770, 749, 703, 695, 676, 627, 615cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.82(d,J=5.4Hz,3H,NCHCH3中のCH3),0.83(dd,J=6.8Hz,3JH-P=20.5Hz,3H,PCHCH3中のCH3),0.90-1.13(m,5H,CH2), 1.17(dd,J=6.8Hz,3JH-P=18.5Hz,3H,PCHCH3中のCH3),1.33-1.40(m,1H,CH2), 1.59-1.69(m,5H,CH2,CH),2.16(s,broad,1H,NH), 2.20-2.30(m,1H,PCH), 3.19-3.28(m,1H,NCH),7.34-7.42(m,3H,Ar), 7.89-7.94(m,2H,Ar).、 13C-NMR(CDCl3):δ16.4(CHCH3中のCH3),16.6(CHCH3中のCH3), 19.2(d,3JC-P=2.5Hz,CHCH3中のCH3),26.1(CH2), 26.2(CH2), 26.4(CH2), 27.8(CH2),29.3(CH2), 32.0(d,1JC-P=62.0Hz,CHCH3においてCH3に結合するCH),44.3(d,JC-P=5.8Hz,CH), 52.4(d,2JC-P=2.3Hz,NCH),127.9(d,JC-P=12.4Hz,Ar), 131.3(d,4JC-P=2.5Hz,Ar),131.9(d,JC-P=9.9Hz,Ar), 133.4(d,1JC-P=79.4Hz,Ar).、 31P-NMR(CDCl3):δ72.7(1JP-Se=741.1Hz).、 77Se-NMR(CDCl3):δ-391.3(d,1JSe-P=741.1Hz).
<質量分析> MS (EI) m/z 357 (M+).
(化合物8b)
<赤外吸収スペクトル(KBr錠剤)> 3288, 3053, 2963, 2926, 2851,1573, 1462, 1448, 1436, 1408, 1383, 1308, 1287, 1249, 1187, 1154, 1142, 1101,1072, 1028, 968, 930, 912, 888, 844, 825, 748, 705, 694, 673, 622, 614cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.73-1.30(m,6H,CH2),0.82(dd,J=6.8Hz,3JH-P=20.5Hz,3H,PCHCH3中のCH3),1.05(d,J=6.8Hz,3H,NCHCH3中のCH3), 1.15(dd,J=6.8Hz,3JH-P=19.0Hz,3H,PCHCH3中のCH3),1.44-1.56(m,5H,CH2,CH), 1.95(s,broad,1H,NH), 2.20-2.34(m,1H,PCH),3.02-3.13(m,1H,NCH), 7.34-7.41(m,3H,Ar), 7.90-7.95(m, 2H, Ar).、 13C-NMR(CDCl3):δ16.3(CHCH3中のCH3),16.4(CHCH3中のCH3), 18.8(d,3JC-P=3.3Hz,CHCH3中のCH3),26.0(CH2), 26.2(CH2), 26.3(CH2), 27.5(CH2),29.3(CH2), 31.8(d,1JC-P=62.0Hz,CHCH3においてCH3に結合するCH),44.1(d,JC-P=5.0Hz,CH), 52.9(d,2JC-P=2.5Hz,NCH),127.8(d,JC-P=12.4Hz,Ar), 131.3(d,4JC-P=2.5Hz,Ar),132.1(d,JC-P=10.8Hz,Ar), 132.3(d,1JC-P=82.7Hz,Ar).、 31P-NMR(CDCl3):δ73.4(1JP-Se=742.7Hz).、 77Se-NMR(CDCl3):δ-382.2(d,1JSe-P=742.7Hz).
<質量分析> MS (EI) m/z 357 (M+).(Compound 8a)
<Infrared absorption spectrum (KBr tablet)> 3298, 3262, 3069, 3050, 2968,2921, 2871, 2851, 1573, 1476, 1463, 1446, 1433, 1410, 1379, 1351, 1308, 1285,1258, 1238, 1189, 1154, 1097, 1073, 1049, 1037, 1028, 1013, 967, 930, 913, 887,873, 843, 824, 770, 749, 703, 695, 676, 627, 615cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.82 (d, J = 5.4Hz, 3H, CH 3 in NCHCH 3), 0.83 (dd, J = 6.8Hz, 3 J HP = 20.5Hz, 3H, CH 3 in PCHCH 3), 0.90-1.13 (m, 5H, CH 2), 1.17 (dd, J = 6.8Hz, 3 J HP = 18.5Hz, 3H, CH 3 in PCHCH 3), 1.33-1.40 (m, 1H, CH 2), 1.59-1.69 (m, 5H, CH 2, CH), 2.16 (s, broad, 1H, NH), 2.20-2.30 (m , 1H, PCH), 3.19-3.28 (m, 1H, NCH), 7.34-7.42 (m, 3H, Ar), 7.89-7.94 (m, 2H, Ar)., 13 C-NMR (CDCl 3 ): δ16 .4 (CHCH CH 3 in 3), 16.6 (CH 3 in CHCH 3), 19.2 (d, 3 J CP = 2.5Hz, CH 3 in CHCH 3), 26.1 (CH 2 ), 26.2 (CH 2 ), 26.4 (CH 2), 27.8 (CH 2), 29.3 (CH 2), 32.0 (d, 1 J CP = 62.0Hz, CH of binding to CH 3 in CHCH 3), 44.3 (d, J CP = 5.8 Hz, CH), 52.4 (d, 2 J CP = 2.3Hz, NCH), 127.9 (d, J CP = 12.4Hz, Ar), 131.3 (d, 4 J CP = 2.5Hz, Ar), 131.9 (d, J CP = 9.9 Hz, Ar), 133.4 (d, 1 J CP = 79.4 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ72.7 ( 1 J P-Se = 741.1 Hz)., 77 Se -NMR (CDCl 3 ): δ-391.3 (d, 1 J Se-P = 741.1 Hz).
<Mass Spectrometry> MS (EI) m / z 357 (M + ).
(Compound 8b)
<Infrared absorption spectrum (KBr tablet)> 3288, 3053, 2963, 2926, 2851,1573, 1462, 1448, 1436, 1408, 1383, 1308, 1287, 1249, 1187, 1154, 1142, 1101,1072, 1028, 968, 930, 912, 888, 844, 825, 748, 705, 694, 673, 622, 614cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.73-1.30 (m, 6H, CH 2 ), 0.82 (dd, J = 6.8 Hz, 3 J HP = 20.5Hz, 3H, CH 3 in PCHCH 3), 1.05 (d, J = 6.8Hz, 3H, CH 3 in NCHCH 3), 1.15 (dd, J = 6.8Hz, 3 J HP = 19.0Hz, 3H, CH 3 in PCHCH 3 ), 1.44-1.56 (m, 5H, CH 2 , CH), 1.95 (s, broad, 1H, NH), 2.20-2.34 (m, 1H, PCH), 3.02-3.13 (m, . 1H, NCH), 7.34-7.41 ( m, 3H, Ar), 7.90-7.95 (m, 2H, Ar), 13 C-NMR (CDCl 3): δ16.3 (CH 3 in CHCH 3), 16.4 (CH 3 in CHCH 3), 18.8 (d, 3 J CP = 3.3Hz, CH 3 in CHCH 3), 26.0 (CH 2 ), 26.2 (CH 2), 26.3 (CH 2), 27.5 (CH 2 ), 29.3 (CH 2), 31.8 (d, 1 J CP = 62.0Hz, CH of binding to CH 3 in CHCH 3), 44.1 (d, J CP = 5.0Hz, CH), 52.9 (d, 2 J CP = 2.5Hz, NCH), 127.8 (d, J CP = 12.4Hz, Ar), 131.3 (d, 4 J CP = 2.5Hz, Ar), 132.1 (d, J CP = 10.8Hz, Ar), 132.3 (d , 1 J CP = 82.7 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 73.4 ( 1 J P-Se = 742.7 Hz)., 77 Se-NMR (CDCl 3 ): δ-382.2 (d , 1 J Se-P = 742.7Hz).
<Mass Spectrometry> MS (EI) m / z 357 (M + ).
以上の結果より、化合物8aは下記式(27)に示した構造を有しており、(RP,S)-N-1-シクロヘキシルエチル-P-1-メチルエチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は40%(収量:0.285g,0.80mmol)であり、融点は105〜107℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-33°であった。From the above results, compound 8a has the structure shown in the following formula (27), and (R P , S) -N-1-cyclohexylethyl-P-1-methylethyl-P-phenylselenophosphinic acid Identified as an amide. The yield of this selenophosphinic acid amide is 40% (yield: 0.285 g, 0.80 mmol), the melting point is 105 to 107 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 33 °.
(化合物9a)
<赤外吸収スペクトル(KBr錠剤)> 3320, 3068, 3045, 2927, 2849,1572, 1479, 1448, 1435, 1400, 1374, 1327, 1309, 1294, 1280, 1235, 1200, 1144,1100, 1061, 1026, 1004, 969, 919, 892, 853, 843, 824, 769, 739, 705, 691, 624cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.82(d,J=6.8Hz,3H,NCHCH3中のCH3),0.85-1.28(m,9H,CH2), 1.37-1.48(m,3H,CH2),1.59-1.66(m,7H,CH2), 1.77-1.80(m,1H,CH2),1.89-1.98(m,2H,CH), 2.14(s,broad,1H,NH), 3.18-3.29(m,1H,NCH),7.34-7.42(m,3H,Ar), 7.88-7.93(m,2H,Ar).、 13C-NMR(CDCl3):δ19.1(d,3JC-P=2.5Hz,NCHCH3中のCH3),25.6(CH2), 25.8(CH2), 25.9(CH2), 26.1(CH2),26.2(CH2), 26.26(CH2), 26.30(CH2), 26.4(CH2),27.9(CH2), 29.4(CH2), 42.1(d,1JC-P=61.2Hz,CH),44.3(d,JC-P=6.6Hz,CH), 52.2(d,2JC-P=1.7Hz,NCH),127.8(d,JC-P=11.6Hz,Ar), 131.2(d,JC-P=2.5Hz,Ar), 132.1(d,4JC-P=10.8Hz,Ar),133.4(d,1JC-P=80.2Hz,Ar).、 31P-NMR(CDCl3):δ68.6(1JP-Se=739.6Hz).、 77Se-NMR(CDCl3):δ-368.1(d,1JSe-P=739.6Hz).
<質量分析> MS (EI) m/z 397 (M+).
(化合物9b)
<赤外吸収スペクトル(KBr錠剤)> 3263, 3071, 3050, 2937, 2851,1574, 1483, 1447, 1435, 1407, 1383, 1334, 1311, 1284, 1268, 1238, 1202, 1178,1152, 1146, 1116, 1100, 1087, 1074, 1014, 1000, 968, 909, 891, 868, 852, 840,822, 774, 753, 740, 703, 694, 614cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.77-2.02(m,23H,CH2,CH,NH),1.17(d,J=6.8Hz,3H,NCHCH3中のCH3), 3.08-3.17(m,1H,NCH),7.40-7.48(m,3H,Ar), 7.93-7.99(m,2H,Ar).、 13C-NMR(CDCl3):δ18.8(d,3JC-P=2.5Hz,CHCH3中のCH3),25.5(CH2), 25.7(CH2), 25.8(CH2), 26.0 (CH2),26.06(CH2), 26.12(CH2), 26.2(CH2), 26.4(CH2),27.4(CH2), 29.4(CH2), 42.0(d,1JC-P=61.2Hz,CH),44.1(d,JC-P=5.8Hz,CH), 52.2(NCH), 127.8(d,JC-P=12.4Hz,Ar),131.3(Ar), 132.3(d,1JC-P=82.7Hz,Ar), 133.0(d,JC-P=9.9Hz,Ar).、 31P-NMR(CDCl3):δ69.1(1JP-Se=738.1Hz).、 77Se-NMR(CDCl3):δ-358.3(d,1JSe-P=738.1Hz).
<質量分析> MS (EI) m/z 397 (M+).(Compound 9a)
<Infrared absorption spectrum (KBr tablet)> 3320, 3068, 3045, 2927, 2849,1572, 1479, 1448, 1435, 1400, 1374, 1327, 1309, 1294, 1280, 1235, 1200, 1144,1100, 1061, 1026, 1004, 969, 919, 892, 853, 843, 824, 769, 739, 705, 691, 624cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.82 (d, J = 6.8Hz, 3H, CH 3 in NCHCH 3), 0.85-1.28 (m, 9H, CH 2 ), 1.37-1.48 (m, 3H, CH 2 ), 1.59-1.66 (m, 7H, CH 2 ), 1.77-1.80 (m, 1H, CH 2 ), 1.89-1.98 (m, 2H, CH), 2.14 (s, broad, 1H, NH), 3.18-3.29 (m, 1H, NCH), 7.34-7.42 (m, 3H, Ar), 7.88-7.93 (m, 2H, Ar), 13 C -NMR (CDCl 3): δ19.1 ( d, 3 J CP = 2.5Hz, CH 3 in NCHCH 3), 25.6 (CH 2 ), 25.8 (CH 2), 25.9 (CH 2), 26.1 (CH 2 ), 26.2 (CH 2 ), 26.26 (CH 2 ), 26.30 (CH 2 ), 26.4 (CH 2 ), 27.9 (CH 2 ), 29.4 (CH 2 ), 42.1 (d, 1 J CP = 61.2 Hz, CH ), 44.3 (d, J CP = 6.6Hz, CH), 52.2 (d, 2 J CP = 1.7Hz, NCH), 127.8 (d, J CP = 11.6Hz, Ar), 131.2 (d, J CP = 2.5 Hz, Ar), 132.1 (d, 4 J CP = 10.8 Hz, Ar), 133.4 (d, 1 J CP = 80.2 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ 68.6 ( 1 J P -Se = 739.6 Hz), 77 Se-NMR (CDCl 3 ): δ-368.1 (d, 1 J Se-P = 739.6 Hz).
<Mass Spectrometry> MS (EI) m / z 397 (M + ).
(Compound 9b)
<Infrared absorption spectrum (KBr tablet)> 3263, 3071, 3050, 2937, 2851,1574, 1483, 1447, 1435, 1407, 1383, 1334, 1311, 1284, 1268, 1238, 1202, 1178,1152, 1146, 1116, 1100, 1087, 1074, 1014, 1000, 968, 909, 891, 868, 852, 840,822, 774, 753, 740, 703, 694, 614cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 0.77-2.02 (m, 23 H, CH 2 , CH, NH), 1.17 (d, J = 6.8 Hz, 3H, CH 3 in NCHCH 3), 3.08-3.17 (m, 1H, NCH), 7.40-7.48 (m, 3H, Ar), 7.93-7.99 (m, 2H, Ar)., 13 C-NMR (CDCl 3 ): δ18.8 (d, 3 J CP = 2.5Hz, CH 3 in CHCH 3 ), 25.5 (CH 2 ), 25.7 (CH 2 ), 25.8 (CH 2 ), 26.0 (CH 2 ), 26.06 ( CH 2 ), 26.12 (CH 2 ), 26.2 (CH 2 ), 26.4 (CH 2 ), 27.4 (CH 2 ), 29.4 (CH 2 ), 42.0 (d, 1 J CP = 61.2 Hz, CH), 44.1 ( d, J CP = 5.8Hz, CH), 52.2 (NCH), 127.8 (d, J CP = 12.4Hz, Ar), 131.3 (Ar), 132.3 (d, 1 J CP = 82.7Hz, Ar), 133.0 ( d, J CP = 9.9 Hz, Ar)., 31 P-NMR (CDCl 3 ): δ69.1 ( 1 J P-Se = 738.1 Hz)., 77 Se-NMR (CDCl 3 ): δ-358.3 (d , 1 J Se-P = 738.1Hz).
<Mass Spectrometry> MS (EI) m / z 397 (M + ).
以上の結果より、化合物9aは下記式(29)に示した構造を有しており、(RP,S)-P-シクロヘキシル-N-1-シクロヘキシルエチル-P-フェニルセレノホスフィン酸アミドであると同定した。このセレノホスフィン酸アミドの収率は44%(収量:0.351g,0.89mmol)であり、融点は92〜94℃であり、旋光度[α]D 20(c 1.00, CH2Cl2)は-33°であった。From the above results, compound 9a has the structure shown in the following formula (29), and is (R P , S) -P -cyclohexyl-N-1-cyclohexylethyl- P -phenylselenophosphinic acid amide. Was identified. The yield of this selenophosphinic acid amide is 44% (yield: 0.351 g, 0.89 mmol), the melting point is 92-94 ° C., and the optical rotation [α] D 20 (c 1.00, CH 2 Cl 2 ) is − It was 33 °.
(化合物10a)
<赤外吸収スペクトル(KBr錠剤)> 3358, 3061, 2974, 1618, 1588,1507, 1460, 1407, 1371, 1322, 1260, 1220, 1201, 1156, 1114, 1068, 1038, 980,868, 858, 830, 772, 565, 530, 512 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.50(d,J=6.3Hz,3H,CH3),3.68(dd,J=5.1Hz,10.0Hz,1H,NH), 4.79-4.90(m,1H,CH), 6.63-8.02(m,17H,Ar).、 13C-NMR(CDCl3):δ24.2(CH3),53.1(CH), 121.2, 121.6, 122.3, 122.5, 125.7, 125.8, 126.4, 126.5, 126.9, 127.0,127.2, 127.7, 128.4, 128.6, 128.8, 130.4, 130.9, 131.6, 132.0, 132.4, 144.1,144.1, 146.4, 146.5, 147.4, 147.6(Ar).、 31P-NMR(CDCl3):δ83.8(1JP-Se=971.1Hz).、 77Se-NMR(CDCl3):δ-301.3(1JSe-P=971.1Hz).
<質量分析> MS (EI) m/z 515 (M+).
<元素分析> Anal Calcd for C28H22NO2PSe(515.06):C,65.38;H,4.31;N,2.72. Found:C,65.37;H,4.24;N,2.67.
(化合物10b)
<赤外吸収スペクトル(KBr錠剤)> 3367, 3055, 2983, 1618, 1587,1502, 1454, 1438, 1378, 1332, 1329, 1259, 1193, 1148, 1110, 1089, 1006, 995,998, 878, 868, 854, 844, 832, 779, 565, 555, 524, 511 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.54(d,J=6.3Hz,3H,CH3),3.74(dd,J=4.9Hz,10.2Hz,1H,NH), 4.60-4.70(m,1H,CH), 6.60-8.00(m,17H,Ar).、 13C-NMR(CDCl3):δ25.3(CH3),53.1(CH), 121.0, 121.6, 122.3, 125.7, 125.8, 125.9, 125.9, 126.5, 126.7, 127.0,127.2, 127.4, 128.4, 128.6, 128.6, 130.6, 130.9, 131.5, 132.0, 132.4, 143.5,143.6, 146.5, 146.6, 147.7, 147.8(Ar).、 31P-NMR(CDCl3):δ82.2(1JP-Se=971.1Hz).、 77Se-NMR(CDCl3):δ-295.6(1JSe-P=971.1Hz).
<質量分析> MS (EI) m/z 515 (M+).
<元素分析> Anal Calcd for C28H22NO2PSe(515.06):C,65.38;H,4.31;N,2.72. Found:C,65.37;H,4.24;N,2.67.(Compound 10a)
<Infrared absorption spectrum (KBr tablet)> 3358, 3061, 2974, 1618, 1588,1507, 1460, 1407, 1371, 1322, 1260, 1220, 1201, 1156, 1114, 1068, 1038, 980,868, 858, 830, 772, 565, 530, 512 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.50 (d, J = 6.3 Hz, 3H, CH 3 ), 3.68 (dd, J = 5.1 Hz, 10.0 Hz, 1H, NH), 4.79-4.90 (m, 1H, CH), 6.63-8.02 (m, 17H, Ar)., 13 C-NMR (CDCl 3 ): δ 24.2 (CH 3 ), 53.1 (CH ), 121.2, 121.6, 122.3, 122.5, 125.7, 125.8, 126.4, 126.5, 126.9, 127.0, 127.2, 127.7, 128.4, 128.6, 128.8, 130.4, 130.9, 131.6, 132.0, 132.4, 144.1, 144.1, 146.4, 146.5, 147.4, 147.6 (Ar)., 31 P-NMR (CDCl 3 ): δ 83.8 ( 1 J P-Se = 971.1 Hz). 77 Se-NMR (CDCl 3 ): δ-301.3 ( 1 J Se-P = 971.1Hz).
<Mass Spectrometry> MS (EI) m / z 515 (M + ).
<Elemental analysis> Anal Calcd for C 28 H 22 NO 2 PSe (515.06): C, 65.38; H, 4.31; N, 2.72 Found: C, 65.37; H, 4.24; N, 2.67.
(Compound 10b)
<Infrared absorption spectrum (KBr tablet)> 3367, 3055, 2983, 1618, 1587, 1502, 1454, 1438, 1378, 1332, 1329, 1259, 1193, 1148, 1110, 1089, 1006, 995,998, 878, 868, 854, 844, 832, 779, 565, 555, 524, 511 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.54 (d, J = 6.3 Hz, 3H, CH 3 ), 3.74 (dd, J = 4.9 Hz, 10.2 Hz, 1H, NH), 4.60-4.70 (m, 1H, CH), 6.60-8.00 (m, 17H, Ar)., 13 C-NMR (CDCl 3 ): δ 25.3 (CH 3 ), 53.1 (CH ), 121.0, 121.6, 122.3, 125.7, 125.8, 125.9, 125.9, 126.5, 126.7, 127.0, 127.2, 127.4, 128.4, 128.6, 128.6, 130.6, 130.9, 131.5, 132.0, 132.4, 143.5, 143.6, 146.5, 146.6, 147.7, 147.8 (Ar)., 31 P-NMR (CDCl 3 ): δ 82.2 ( 1 J P-Se = 971.1 Hz). 77 Se-NMR (CDCl 3 ): δ-295.6 ( 1 J Se-P = 971.1Hz).
<Mass Spectrometry> MS (EI) m / z 515 (M + ).
<Elemental analysis> Anal Calcd for C 28 H 22 NO 2 PSe (515.06): C, 65.38; H, 4.31; N, 2.72 Found: C, 65.37; H, 4.24; N, 2.67.
以上の結果より、化合物10aは下記式(31)及び下記式(32)のどちらか一方に示した構造を有しており、化合物10bは他方に示した構造を有していた。よって、これら化合物10a及び10bは(R)-O,O-ビナフチル-N-1-フェニルエチルセレノリン酸アミドであると同定した。化合物10aの収率は35%(収量:0.540g,1.05mmol)であり、融点は294〜296℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-322°であった。一方、化合物10bの収率は54%(収量:0.834g,1.62mmol)であり、融点は221〜223℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-276°であった。このセレノリン酸アミドは新規化合物であり、空気中で安定であった。From the above results, compound 10a had a structure represented by one of the following formulas (31) and (32), and compound 10b had a structure represented by the other. Therefore, these compounds 10a and 10b were identified as (R) -O, O-binaphthyl-N-1-phenylethylselenophosphoric acid amide. The yield of compound 10a was 35% (yield: 0.540 g, 1.05 mmol), the melting point was 294-296 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −322 °. . On the other hand, the yield of compound 10b is 54% (yield: 0.834 g, 1.62 mmol), the melting point is 221 to 223 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) is −276 °. there were. This selenophosphoric acid amide is a novel compound and was stable in the air.
(化合物11a)
<赤外吸収スペクトル(KBr錠剤)> 3367, 3051, 2970, 1931, 1691,1588, 1508, 1461, 1428, 1371, 1258, 1223, 1173, 1155, 1068, 984, 952, 836, 798,751, 706, 696, 650, 627, 612, 566, 524, 508 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.57(d,J=6.3Hz,3H,CH3),3.87(dd,J=7.3Hz,9.8Hz,1H,NH), 5.43-5.53(m,1H,CH), 6.65-8.04(m,19H,Ar).、 13C-NMR(CDCl3):δ24.7(CH3),49.3(CH), 121.0, 121.5, 122.2, 122.4, 122.7, 123.0, 125.3, 125.6, 125.8, 126.4,126.5, 126.7, 126.9, 127.2, 128.1, 128.3, 128.5, 128.8, 130.2, 130.4, 130.8,131.5, 132.4, 133.8, 139.8, 139.9, 146.4, 146.5, 147.6, 147.8(Ar).、 31P-NMR(CDCl3):δ83.1(1JP-Se=974.2Hz).、 77Se-NMR(CDCl3):δ-302.5(1JSe-P=974.2Hz).
<質量分析> MS (EI) m/z 565 (M+).
<元素分析> Anal Calcd for C32H24NO2PSe(565.07):C,68.09;H,4.29;N,2.48. Found:C,68.07;H,4.31;N,2.48.
(化合物11b)
<赤外吸収スペクトル(KBr錠剤)> 3367, 3055, 2983, 1618, 1587,1502, 1454, 1438, 1378, 1332, 1329, 1259, 1193, 1148, 1110, 1089, 1006, 995,998, 878, 868, 854, 844, 832, 779, 565, 555, 524, 511 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.64(d,J=6.8Hz,3H,CH3),4.07(dd,J=7.3Hz,9.8Hz,1H), 5.24-5.34(m,1H,CH), 6.67-8.04(m,19H,Ar).、 13C-NMR(CDCl3):δ24.8(CH3),49.5(CH), 120.5, 121.6, 121.9, 122.3, 122.8, 125.3, 125.5, 125.6, 125.8, 126.2,126.5, 127.0, 128.1, 128.4, 128.5, 128.6, 130.1, 130.2, 130.9, 131.3, 132.0,132.2, 132.4, 133.8, 139.5, 139.6, 146.5, 146.6, 147.6, 147.7(Ar).、 31P-NMR(CDCl3):δ80.3(1JP-Se=971.2Hz).、 77Se-NMR(CDCl3):δ-297.0(1JSe-P=971.2Hz).
<質量分析> MS (EI) m/z 565 (M+).
<元素分析> Anal Calcd for C32H24NO2PSe(565.07):C,68.09;H,4.29;N,2.48. Found:C,68.07;H,4.31;N,2.48.(Compound 11a)
<Infrared absorption spectrum (KBr tablet)> 3367, 3051, 2970, 1931, 1691,1588, 1508, 1461, 1428, 1371, 1258, 1223, 1173, 1155, 1068, 984, 952, 836, 798,751, 706, 696, 650, 627, 612, 566, 524, 508 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.57 (d, J = 6.3 Hz, 3H, CH 3 ), 3.87 (dd, J = 7.3 Hz, 9.8 Hz, 1H, NH), 5.43-5.53 (m, 1H, CH), 6.65-8.04 (m, 19H, Ar)., 13 C-NMR (CDCl 3 ): δ 24.7 (CH 3 ), 49.3 (CH ), 121.0, 121.5, 122.2, 122.4, 122.7, 123.0, 125.3, 125.6, 125.8, 126.4, 126.5, 126.7, 126.9, 127.2, 128.1, 128.3, 128.5, 128.8, 130.2, 130.4, 130.8, 131.5, 132.4, 133.8, 139.8, 139.9, 146.4, 146.5, 147.6, 147.8 (Ar)., 31 P-NMR (CDCl 3 ): δ 83.1 ( 1 J P-Se = 974.2 Hz). 77 Se-NMR (CDCl 3 ): δ -302.5 ( 1 J Se-P = 974.2Hz).
<Mass Spectrometry> MS (EI) m / z 565 (M + ).
<Elemental analysis> Anal Calcd for C 32 H 24 NO 2 PSe (565.07): C, 68.09; H, 4.29; N, 2.48. Found: C, 68.07; H, 4.31; N, 2.48.
(Compound 11b)
<Infrared absorption spectrum (KBr tablet)> 3367, 3055, 2983, 1618, 1587, 1502, 1454, 1438, 1378, 1332, 1329, 1259, 1193, 1148, 1110, 1089, 1006, 995,998, 878, 868, 854, 844, 832, 779, 565, 555, 524, 511 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.64 (d, J = 6.8 Hz, 3H, CH 3 ), 4.07 (dd, J = 7.3 Hz, 9.8 Hz, 1H), 5.24-5.34 (m, 1H, CH), 6.67-8.04 (m, 19H, Ar)., 13 C-NMR (CDCl 3 ): δ 24.8 (CH 3 ), 49.5 (CH), 120.5, 121.6, 121.9, 122.3, 122.8, 125.3, 125.5, 125.6, 125.8, 126.2,126.5, 127.0, 128.1, 128.4, 128.5, 128.6, 130.1, 130.2, 130.9, 131.3, 132.0,132.2, 132.4, 133.8, 139.5, 139.6, 146.5, 146.6, 147.6, 147.7 (Ar)., 31 P-NMR (CDCl 3 ): δ 80.3 ( 1 J P-Se = 971.2 Hz). 77 Se-NMR (CDCl 3 ): δ-297.0 ( 1 J Se-P = 971.2Hz).
<Mass Spectrometry> MS (EI) m / z 565 (M + ).
<Elemental analysis> Anal Calcd for C 32 H 24 NO 2 PSe (565.07): C, 68.09; H, 4.29; N, 2.48. Found: C, 68.07; H, 4.31; N, 2.48.
以上の結果より、化合物11aは下記式(33)及び下記式(34)のどちらか一方に示した構造を有しており、化合物11bは他方に示した構造を有していた。よって、これら化合物11a及び11bは(R)-O,O-ビナフチル-N-1-ナフチルエチルセレノリン酸アミドであると同定した。化合物11aの収率は35%(収量:0.594g,1.05mmol)であり、融点は257〜259℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-450°であった。一方、化合物11bの収率は57%(収量:0.966g,1.71mmol)であり、融点は270〜272℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-261°であった。このセレノリン酸アミドは新規化合物であり、空気中で安定であった。From the above results, compound 11a had a structure represented by either the following formula (33) or formula (34), and compound 11b had a structure represented by the other. Therefore, these compounds 11a and 11b were identified as (R) -O, O-binaphthyl-N-1-naphthylethylselenophosphoric acid amide. The yield of compound 11a was 35% (yield: 0.594 g, 1.05 mmol), the melting point was 257-259 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −450 °. . On the other hand, the yield of compound 11b is 57% (yield: 0.966 g, 1.71 mmol), the melting point is 270 to 272 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) is −261 °. there were. This selenophosphoric acid amide is a novel compound and was stable in the air.
(化合物12a)
<赤外吸収スペクトル(KBr錠剤)> 3253, 3056, 2966, 2930, 2871,1619, 1587, 1507, 1460, 1414, 1359, 1292, 1255, 1223, 1120, 1066, 1019, 980,948, 851, 772, 754, 697, 651, 613, 566, 531, 510 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.85(t,J=7.3Hz,3H,CH2CH3中のCH3),1.21(d,J=6.4Hz,3H,CHCH3中のCH3), 1.40-1.48(m,2H,CH2),3.23(m,1H,NH), 3.38-3.48(m,1H,CH), 7.22-7.60(m,8H,Ar), 7.91-8.02(m,4H,Ar).、 13C-NMR(CDCl3):δ10.3(CHCH3中のCH3),23.1(CHCH3中のCH3), 31.4(CH2), 51.5(CHCH3中のCH3),121.1, 121.7, 122.3, 122.5, 125.6, 125.8, 126.5, 126.8, 127.0, 127.2, 128.5,130.6, 130.9, 131.5, 131.9, 132.5, 146.5, 146.6, 147.7, 147.8(Ar).、 31P-NMR(CDCl3):δ83.6(1JP-Se=966.7Hz).、 77Se-NMR(CDCl3):δ-297.9(1JSe-P=966.7Hz).
<質量分析> MS (EI) m/z 467 (M+).
<元素分析> Anal Calcd for C24H22NO2PSe(467.06):C,61.81;H,4.75;N,3.00. Found:C,61.66;H,4.75;N,2.92.
(化合物12b)
<赤外吸収スペクトル(KBr錠剤)> 3253, 3056, 2966, 2930, 2871,1619, 1587, 1507, 1460, 1414, 1359, 1292, 1255, 1223, 1120, 1066, 1019, 980,948, 851, 772, 754, 697, 651, 613, 566, 531, 510 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.93(t,J=7.5Hz,3H,CH2CH3中のCH3),1.12(d,J=6.3Hz,3H,CHCH3中のCH3), 1.55-1.61(m,2H,CH2),3.23(m,1H,NH), 3.40-3.55(m,1H,CH), 7.24-7.61(m,8H,Ar), 7.92-8.03(m,4H,Ar).、 13C-NMR(CDCl3):δ10.3(CHCH3中のCH3),22.1(CHCH3中のCH3), 33.4(CH2), 51.7(CHCH3中のCH3),121.1, 121.7, 122.3, 122.5, 125.6, 125.8, 126.5, 126.8, 127.0, 127.3, 128.5,130.6, 130.9, 131.5, 131.9, 132.4, 146.5, 146.6, 147.7, 147.8(Ar).、 31P-NMR(CDCl3):δ83.3(1JP-Se=966.8Hz).、 77Se-NMR(CDCl3):δ-299.3(1JSe-P=966.8Hz).
<質量分析> MS (EI) m/z 467 (M+).
<元素分析> Anal Calcd for C24H22NO2PSe(467.06):C,61.81;H,4.75;N,3.00. Found:C,61.66;H,4.75;N,2.92.(Compound 12a)
<Infrared absorption spectrum (KBr tablet)> 3253, 3056, 2966, 2930, 2871,1619, 1587, 1507, 1460, 1414, 1359, 1292, 1255, 1223, 1120, 1066, 1019, 980,948, 851, 772, 754, 697, 651, 613, 566, 531, 510 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.85 (t, J = 7.3Hz, 3H, CH 3 in the CH 2 CH 3), 1.21 ( d, J = 6.4Hz, 3H, CH 3 in CHCH 3), 1.40-1.48 (m, 2H, CH 2), 3.23 (m, 1H, NH), 3.38-3.48 (m, 1H, CH), 7.22-7.60 . (m, 8H, Ar) , 7.91-8.02 (m, 4H, Ar), 13 C-NMR (CDCl 3): δ10.3 (CH 3 in CHCH 3), 23.1 (CH 3 in CHCH 3) , 31.4 (CH 2 ), 51.5 (CH 3 in CHCH 3 ), 121.1, 121.7, 122.3, 122.5, 125.6, 125.8, 126.5, 126.8, 127.0, 127.2, 128.5, 130.6, 130.9, 131.5, 131.9, 132.5, 146.5 , 146.6, 147.7, 147.8 (Ar)., 31 P-NMR (CDCl 3 ): δ 83.6 ( 1 J P-Se = 966.7 Hz), 77 Se-NMR (CDCl 3 ): δ-297.9 ( 1 J (Se-P = 966.7Hz).
<Mass spectrometry> MS (EI) m / z 467 (M + ).
<Elemental analysis> Anal Calcd for C 24 H 22 NO 2 PSe (467.06):. C, 61.81; H, 4.75; N, 3.00 Found: C, 61.66; H, 4.75; N, 2.92.
(Compound 12b)
<Infrared absorption spectrum (KBr tablet)> 3253, 3056, 2966, 2930, 2871,1619, 1587, 1507, 1460, 1414, 1359, 1292, 1255, 1223, 1120, 1066, 1019, 980,948, 851, 772, 754, 697, 651, 613, 566, 531, 510 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.93 (t, J = 7.5Hz, 3H, CH 3 in the CH 2 CH 3), 1.12 ( d, J = 6.3Hz, 3H, CH 3 in CHCH 3), 1.55-1.61 (m, 2H, CH 2), 3.23 (m, 1H, NH), 3.40-3.55 (m, 1H, CH), 7.24-7.61 . (m, 8H, Ar) , 7.92-8.03 (m, 4H, Ar), 13 C-NMR (CDCl 3): δ10.3 (CH 3 in CHCH 3), 22.1 (CH 3 in CHCH 3) , 33.4 (CH 2 ), 51.7 (CH 3 in CHCH 3 ), 121.1, 121.7, 122.3, 122.5, 125.6, 125.8, 126.5, 126.8, 127.0, 127.3, 128.5, 130.6, 130.9, 131.5, 131.9, 132.4, 146.5 , 146.6, 147.7, 147.8 (Ar)., 31 P-NMR (CDCl 3 ): δ 83.3 ( 1 J P-Se = 966.8 Hz), 77 Se-NMR (CDCl 3 ): δ-299.3 ( 1 J (Se-P = 966.8Hz).
<Mass spectrometry> MS (EI) m / z 467 (M + ).
<Elemental analysis> Anal Calcd for C 24 H 22 NO 2 PSe (467.06):. C, 61.81; H, 4.75; N, 3.00 Found: C, 61.66; H, 4.75; N, 2.92.
以上の結果より、化合物12aは下記式(35)及び下記式(36)のどちらか一方に示した構造を有しており、化合物12bは他方に示した構造を有していた。よって、これら化合物12a及び12bは(R)-O,O-ビナフチル-N-1-メチルプロピルセレノリン酸アミドであると同定した。化合物12aの収率は45%(収量:0.645g,1.38mmol)であり、融点は268〜269℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-385°であった。一方、化合物12bの収率は49%(収量:0.687g,1.47mmol)であり、融点は211〜212℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-366°であった。このセレノリン酸アミドは新規化合物であり、空気中で安定であった。From the above results, compound 12a had a structure represented by either the following formula (35) or formula (36), and compound 12b had a structure represented by the other. Therefore, these compounds 12a and 12b were identified as (R) -O, O-binaphthyl-N-1-methylpropylselenophosphoric acid amide. The yield of compound 12a was 45% (yield: 0.645 g, 1.38 mmol), the melting point was 268-269 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −385 °. . On the other hand, the yield of compound 12b is 49% (yield: 0.687 g, 1.47 mmol), the melting point is 211 to 212 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) is −366 °. there were. This selenophosphoric acid amide is a novel compound and was stable in the air.
(化合物13a)
<赤外吸収スペクトル(KBr錠剤)> 3251, 3056, 2959, 1619, 1587,1507, 1461, 1411, 1369, 1133, 1115, 1070, 981, 940, 832, 771, 750, 696, 651,610, 563, 535, 517cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.84(d,J=6.8Hz,3H,CH(CH3)2中のCH3),0.88(d,J=6.8Hz,3H,CH(CH3)2中のCH3),1.20(d,J=6.3Hz,3H,CHCH3中のCH3), 1.68-1.78(m,1H,CH(CH3)2においてCH3に結合するCH),3.28(dd,J=5.6Hz,10.0Hz,1H,NH), 3.45-3.56(m,1H,CHCH3においてCH3に結合するCH),7.18-7.56(m,8H,Ar), 7.87-7.97(m,4H,Ar).、 13C-NMR(CDCl3):δ17.7(CH3),18.7(CH(CH3)2中のCH3), 19.7(CH(CH3)2中のCH3),34.2(CH(CH3)2においてCH3に結合するCH), 54.7(NCH(CH3)中のNに結合するCH),121.1, 121.7, 121.9, 122.3, 122.6, 125.6, 126.5, 126.8, 128.4, 128.6, 130.6,130.8, 131.5, 131.9, 132.4, 132.5, 146.6, 146.6, 147.6, 147.7(Ar).、 31P-NMR(CDCl3):δ84.8(1JP-Se=966.6Hz).、 77Se-NMR(CDCl3):δ-300.9(1JSe-P=966.6Hz).
<質量分析> MS (EI) m/z 481 (M+).
<元素分析> Anal Calcd for C25H24NO2PSe(481.07):C,62.50;H,5.04;N,2.92. Found:C,62.31;H,5.09;N,2.87.
(化合物13b)
<赤外吸収スペクトル(KBr錠剤)> 3258, 3065, 3013, 2968, 1617,1557, 1518, 1464, 1423, 1351, 1134, 1106, 1072, 981, 946, 842, 770, 753, 699,654, 611, 566, 535, 517 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ0.89(d,J=6.8Hz,3H,CH(CH3)2中のCH3),0.93(d,J=6.8Hz,3H,CH(CH3)2中のCH3),1.07(d,J=6.3Hz,3H,CHCH3中のCH3), 1.65-1.70(m,1H,CH(CH3)2においてCH3に結合するCH),3.28(dd,J=5.6Hz,10.0Hz,1H,NH), 3.37-3.49(m,1H,CHCH3においてCH3に結合するCH),7.17-7.55(m,8H,Ar), 7.85-7.97(m,4H,Ar).、 13C-NMR(CDCl3):δ17.7(CH3),18.7(CH(CH3)2中のCH3), 19.7(CH(CH3)2中のCH3),34.2(CH(CH3)2においてCH3に結合するCH), 54.7(NCH(CH3)においてNに結合するCH),121.1, 121.7, 121.9, 122.3, 122.6, 125.6, 126.5, 126.8, 128.4, 128.6, 130.6,130.8, 131.5, 131.9, 132.4, 132.5, 146.6, 146.6, 147.6, 147.7(Ar).、 31P-NMR(CDCl3):δ84.7(1JP-Se=966.7Hz).、 77Se-NMR(CDCl3):δ-304.8(1JSe-P=966.7Hz).
<質量分析> MS (EI) m/z 481 (M+).
<元素分析> Anal Calcd for C25H24NO2PSe(481.07):C,62.50;H,5.04;N,2.92. Found:C,62.31;H,5.09;N,2.87.(Compound 13a)
<Infrared absorption spectrum (KBr tablet)> 3251, 3056, 2959, 1619, 1587, 1507, 1461, 1411, 1369, 1133, 1115, 1070, 981, 940, 832, 771, 750, 696, 651,610, 563, 535, 517cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.84 (d, J = 6.8Hz, 3H, CH (CH 3) CH 3 in 2), 0.88 ( d, J = 6.8Hz, 3H, CH (CH 3) CH 3 in 2), 1.20 (d, J = 6.3Hz, 3H, CH 3 in CHCH 3), 1.68-1.78 (m, 1H, CH ( CH 3) CH to bind to CH 3 in 2), 3.28 (dd, J = 5.6Hz, 10.0Hz, 1H, NH), 3.45-3.56 (m, 1H, CH of binding to CH 3 in CHCH 3), 7.18 -7.56 (m, 8H, Ar), 7.87-7.97 (m, 4H, Ar)., 13 C-NMR (CDCl 3 ): δ 17.7 (CH 3 ), 18.7 (CH in CH (CH 3 ) 2 3), 19.7 (CH (CH 3) CH 3 in 2), 34.2 (CH (CH 3) CH to bind to CH 3 in 2), 54.7 (NCH (CH 3) CH which bind to N in), 121.1, 121.7, 121.9, 122.3, 122.6, 125.6, 126.5, 126.8, 128.4, 128.6, 130.6, 130.8, 131.5, 131.9, 132.4, 132.5, 146.6, 146.6, 147.6, 147.7 (Ar)., 31 P-NMR (CDCl 3 ): δ 84.8 ( 1 J P-Se = 966.6Hz). 77 Se-NMR (CDCl 3 ): δ-300.9 ( 1 J Se-P = 966.6Hz).
<Mass Spectrometry> MS (EI) m / z 481 (M + ).
<Elemental analysis> Anal Calcd for C 25 H 24 NO 2 PSe (481.07):. C, 62.50; H, 5.04; N, 2.92 Found: C, 62.31; H, 5.09; N, 2.87.
(Compound 13b)
<Infrared absorption spectrum (KBr tablet)> 3258, 3065, 3013, 2968, 1617,1557, 1518, 1464, 1423, 1351, 1134, 1106, 1072, 981, 946, 842, 770, 753, 699,654, 611, 566, 535, 517 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3, TMS internal standard)> 1 H-NMR (CDCl 3): δ0.89 (d, J = 6.8Hz, 3H, CH (CH 3) CH 3 in 2), 0.93 ( d, J = 6.8Hz, 3H, CH (CH 3) CH 3 in 2), 1.07 (d, J = 6.3Hz, 3H, CH 3 in CHCH 3), 1.65-1.70 (m, 1H, CH ( CH 3) CH to bind to CH 3 in 2), 3.28 (dd, J = 5.6Hz, 10.0Hz, 1H, NH), 3.37-3.49 (m, 1H, CH of binding to CH 3 in CHCH 3), 7.17 -7.55 (m, 8H, Ar), 7.85-7.97 (m, 4H, Ar)., 13 C-NMR (CDCl 3 ): δ 17.7 (CH 3 ), 18.7 (CH in CH (CH 3 ) 2 3), 19.7 (CH (CH 3) CH 3 in 2), 34.2 (CH (CH 3) CH to bind to CH 3 in 2), 54.7 (NCH (CH 3) CH which bind to N in), 121.1 , 121.7, 121.9, 122.3, 122.6, 125.6, 126.5, 126.8, 128.4, 128.6, 130.6, 130.8, 131.5, 131.9, 132.4, 132.5, 146.6, 146.6, 147.6, 147.7 (Ar)., 31 P-NMR (CDCl 3 ): Δ 84.7 ( 1 J P-Se = 966.7 Hz). 77 Se-NMR (CDCl 3 ): δ-304.8 ( 1 J Se-P = 966.7 Hz).
<Mass Spectrometry> MS (EI) m / z 481 (M + ).
<Elemental analysis> Anal Calcd for C 25 H 24 NO 2 PSe (481.07):. C, 62.50; H, 5.04; N, 2.92 Found: C, 62.31; H, 5.09; N, 2.87.
以上の結果より、化合物13aは下記式(37)及び下記式(38)のどちらか一方に示した構造を有しており、化合物13bは他方に示した構造を有していた。よって、これら化合物13a及び13bは(R)-O,O-ビナフチル-N-1,2-ジメチルプロピルセレノリン酸アミドであると同定した。化合物13aの収率は44%(収量:0.633g,1.32mmol)であり、融点は273〜274℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-373°であった。一方、化合物13bの収率は48%(収量:0.691g,1.44mmol)であり、融点は212〜213℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-365°であった。このセレノリン酸アミドは新規化合物であり、空気中で安定であった。From the above results, Compound 13a had a structure represented by either the following formula (37) or the following formula (38), and Compound 13b had a structure represented by the other. Therefore, these compounds 13a and 13b were identified as (R) -O, O-binaphthyl-N-1,2-dimethylpropylselenophosphoric acid amide. The yield of compound 13a was 44% (yield: 0.633 g, 1.32 mmol), the melting point was 273 to 274 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −373 °. . On the other hand, the yield of compound 13b is 48% (yield: 0.691 g, 1.44 mmol), the melting point is 212 to 213 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) is −365 °. there were. This selenophosphoric acid amide is a novel compound and was stable in the air.
(化合物14a)
<赤外吸収スペクトル(KBr錠剤)> 3054, 2935, 2864, 1618, 1589,1507, 1461, 1432, 1389, 1322, 1267, 1225, 1208, 1157, 1133, 1085, 1063, 1014,999, 979, 951, 916, 888, 866, 835, 810, 771, 749, 716, 698, 686, 650, 648, 595,568, 528, 503, 485 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.63(d,J=6.8Hz,3H,CH3),1.26-1.37(m,2H,CH2), 1.42-1.45(m,1H,CH2),1.57-1.61(m,2H,CH2), 1.76-1.85(m,1H,CH2),2.88-2.99(m,1H,NCH2), 3.30-3.37(m,1H,NCH2), 4.26-4.35(m,1H,NCH),
7.21-7.62(m,8H,Ar), 7.92-8.05(m,4H,Ar).、 13C-NMR(CDCl3):δ16.2(CH3),18.4(CH2), 26.0(CH2), 30.8(NCH), 41.4(CH2),49.8(NCH2), 121.2, 121.7, 122.2, 125.5, 125.6, 126.4, 126.6, 127.1,127.4, 128.4, 128.5, 130.4, 130.7, 131.3, 131.9, 132.5, 147.1, 147.2, 148.9,149.1(Ar).、 31P-NMR(CDCl3):δ85.3(1JP-Se=960.0Hz).、 77Se-NMR(CDCl3):δ-299.1(1JSe-P=960.0Hz).
<質量分析> MS (EI) m/z 493 (M+).
<元素分析> Anal Calcd for C26H24NO2PSe(493.07):C,63.24;H,4.91;N,2.84. Found:C,63.42;H,5.18;N,2.84.
(化合物14b)
<赤外吸収スペクトル(KBr錠剤)> 3054, 2936, 2864, 1619, 1589,1507, 1461, 1432, 1375, 1322, 1267, 1225, 1208, 1158, 1135, 1087, 1064, 1014,1000, 979, 951, 916, 889, 867, 854, 698, 686, 650, 619, 596, 568, 529, 502,485, 455 cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.33(d,J=6.8Hz,3H,CH3),1.39-1.43(m,2H,CH2), 1.48-1.52(m,1H,CH2),1.56-1.58(m,2H,CH2), 1.63-1.72(m,1H,CH2),2.71-2.80(m,1H,NCH2), 3.35-3.41(m,1H,NCH2), 4.31-4.40(m,1H,NCH),7.21-7.62(m, 8H, Ar ), 7.92-8.05 (m, 4H,Ar).、 13C-NMR(CDCl3):δ16.8(CH3),18.6(CH2), 26.3(CH2), 30.3(NCH), 41.6(CH2),49.8(NCH2), 121.0, 122.1, 122.2, 125.5, 125.6, 126.4, 126.6, 127.1,127.3, 128.4, 128.5, 130.6, 130.8, 131.4, 131.9, 132.4, 147.1, 147.2, 148.9,149.1(Ar).、 31P-NMR(CDCl3):δ86.1(1JP-Se=963.6Hz).、 77Se-NMR(CDCl3):δ-303.7(1JSe-P=963.6Hz).
<質量分析> MS (EI) m/z 493 (M+).
<元素分析> Anal Calcd for C26H24NO2PSe(493.07):C,63.24;H,4.91;N,2.84. Found:C,63.42;H,5.18;N,2.84.(Compound 14a)
<Infrared absorption spectrum (KBr tablet)> 3054, 2935, 2864, 1618, 1589,1507, 1461, 1432, 1389, 1322, 1267, 1225, 1208, 1157, 1133, 1085, 1063, 1014,999, 979, 951, 916, 888, 866, 835, 810, 771, 749, 716, 698, 686, 650, 648, 595,568, 528, 503, 485 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.63 (d, J = 6.8 Hz, 3H, CH 3 ), 1.26-1.37 (m, 2H, CH 2 ), 1.42-1.45 (m, 1H, CH 2 ), 1.57-1.61 (m, 2H, CH 2 ), 1.76-1.85 (m, 1H, CH 2 ), 2.88-2.99 (m, 1H, NCH 2 ), 3.30-3.37 (m, 1H, NCH 2 ), 4.26-4.35 (m, 1H, NCH),
7.21-7.62 (m, 8H, Ar), 7.92-8.05 (m, 4H, Ar)., 13 C-NMR (CDCl 3 ): δ 16.2 (CH 3 ), 18.4 (CH 2 ), 26.0 (CH 2 ), 30.8 (NCH), 41.4 (CH 2 ), 49.8 (NCH 2 ), 121.2, 121.7, 122.2, 125.5, 125.6, 126.4, 126.6, 127.1, 127.4, 128.4, 128.5, 130.4, 130.7, 131.3, 131.9, 132.5 , 147.1, 147.2, 148.9, 149.1 (Ar)., 31 P-NMR (CDCl 3 ): δ 85.3 ( 1 J P-Se = 960.0 Hz). 77 Se-NMR (CDCl 3 ): δ-299.1 ( (1 J Se-P = 960.0Hz).
<Mass Spectrometry> MS (EI) m / z 493 (M + ).
<Elemental analysis> Anal Calcd for C 26 H 24 NO 2 PSe (493.07): C, 63.24; H, 4.91; N, 2.84. Found: C, 63.42; H, 5.18; N, 2.84.
(Compound 14b)
<Infrared absorption spectrum (KBr tablet)> 3054, 2936, 2864, 1619, 1589, 1507, 1461, 1432, 1375, 1322, 1267, 1225, 1208, 1158, 1135, 1087, 1064, 1014,1000, 979, 951, 916, 889, 867, 854, 698, 686, 650, 619, 596, 568, 529, 502,485, 455 cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ1.33 (d, J = 6.8Hz, 3H, CH 3 ), 1.39-1.43 (m, 2H, CH 2 ), 1.48-1.52 (m, 1H, CH 2 ), 1.56-1.58 (m, 2H, CH 2 ), 1.63-1.72 (m, 1H, CH 2 ), 2.71-2.80 (m, 1H, NCH 2 ), 3.35-3.41 (m, 1H, NCH 2 ), 4.31-4.40 (m, 1H, NCH), 7.21-7.62 (m, 8H, Ar), 7.92-8.05 (m, 4H, Ar)., 13 C-NMR (CDCl 3 ): δ 16.8 (CH 3 ), 18.6 (CH 2 ), 26.3 (CH 2 ), 30.3 (NCH), 41.6 (CH 2 ), 49.8 (NCH 2 ), 121.0, 122.1, 122.2, 125.5, 125.6, 126.4, 126.6, 127.1, 127.3, 128.4, 128.5, 130.6, 130.8, 131.4, 131.9, 132.4, 147.1, 147.2, 148.9, 149.1 (Ar)., 31 P-NMR (CDCl 3 ): δ 86.1 ( 1 J P-Se = 963.6 Hz), 77 Se-NMR (CDCl 3 ): δ-303.7 ( 1 J Se-P = 963.6 Hz).
<Mass Spectrometry> MS (EI) m / z 493 (M + ).
<Elemental analysis> Anal Calcd for C 26 H 24 NO 2 PSe (493.07): C, 63.24; H, 4.91; N, 2.84. Found: C, 63.42; H, 5.18; N, 2.84.
以上の結果より、化合物14aは下記式(39)及び下記式(40)のどちらか一方に示した構造を有しており、化合物14bは他方に示した構造を有していた。よって、これら化合物14a及び14bは1-(4-セレニドジナフトジオキサホスフェピニル)-2-メチルピペリジンであると同定した。化合物14aの収率は36%(収量:0.531g,1.08mmol)であり、融点は214〜215℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-434°であった。一方、化合物14bの収率は58%(収量:0.856g,1.74mmol)であり、融点は238〜239℃であり、旋光度[α]D 20(c 0.50, CHCl3)は-376°であった。このセレノリン酸アミドは新規化合物であり、空気中で安定であった。From the above results, compound 14a had a structure represented by either the following formula (39) or formula (40), and compound 14b had a structure represented by the other. Therefore, these compounds 14a and 14b were identified as 1- (4-selenidodinaphthodioxaphosfepinyl) -2-methylpiperidine. The yield of compound 14a was 36% (yield: 0.531 g, 1.08 mmol), the melting point was 214 to 215 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −434 °. . On the other hand, the yield of compound 14b was 58% (yield: 0.856 g, 1.74 mmol), the melting point was 238 to 239 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) was −376 °. there were. This selenophosphoric acid amide is a novel compound and was stable in the air.
(化合物15a)
<赤外吸収スペクトル(KBr錠剤)> 3058, 2928, 1957, 1619, 1589,1500, 1462, 1375, 1321, 1278, 1224, 1201, 1156, 1136, 1069, 792, 748, 717, 696,677, 659, 649, 632, 607, 564, 545, 531, 517cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.40(d,J=6.8Hz,6H,CH3),5.25-5.35(m,2H,CH), 7.11-7.49(m,18H,Ar), 7.88-8.00(m,4H,Ar).、 13C-NMR(CDCl3):δ20.4(CH3),55.0(CH), 121.3, 122.0, 122.2, 122.5, 125.6, 126.4, 126.6, 127.0, 127.1, 127.3,127.7, 128.0, 128.3, 128.5, 130.4, 130.6, 131.2, 131.9, 132.5, 132.6, 141.1,141.2, 146.0, 146.1, 148.7, 148.9(Ar).、 31P-NMR(CDCl3):δ87.2(1JP-Se=959.1Hz).、 77Se-NMR(CDCl3):δ-175.1(1JSe-P=959.1Hz).
<質量分析> MS (EI) m/z 619 (M+).
<元素分析> Anal Calcd for C36H30NO2PSe(619.12):C,69.90;H,4.89;N,2.26. Found:C,69.84;H,4.89;N,2.13.
(化合物15b)
<赤外吸収スペクトル(KBr錠剤)> 3058, 2928, 1957, 1619, 1589,1506, 1462, 1375, 1321, 1278, 1224, 1201, 1156, 1146, 1069, 792, 748, 717, 696,677, 659, 649, 632, 607, 564, 545, 531, 517cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ1.65(d,J=7.3Hz,6H,CH3),5.11-5.23(m,2H,CH), 6.75-7.97(m,22H,Ar).、 13C-NMR(CDCl3):δ19.0(CH3),55.8(CH), 120.6, 122.2, 125.2, 125.4, 125.7, 126.0, 126.2, 126.8, 126.9, 127.1,127.3, 127.6, 127.8, 127.9, 128.4, 128.5, 130.1, 130.5, 131.3, 131.8, 132.4, 141.5,141.6, 146.0, 146.1, 148.4, 148.6(Ar).、 31P-NMR(CDCl3):δ87.8(1JP-Se=957.6Hz).、 77Se-NMR(CDCl3):δ-206.5(1JSe-P=957.6Hz).
<質量分析> MS (EI) m/z 619 (M+).(Compound 15a)
<Infrared absorption spectrum (KBr tablet)> 3058, 2928, 1957, 1619, 1589,1500, 1462, 1375, 1321, 1278, 1224, 1201, 1156, 1136, 1069, 792, 748, 717, 696,677, 659, 649, 632, 607, 564, 545, 531, 517cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.40 (d, J = 6.8Hz, 6H, CH 3 ), 5.25-5.35 (m, 2H, CH) , 7.11-7.49 (m, 18H, Ar), 7.88-8.00 (m, 4H, Ar)., 13 C-NMR (CDCl 3 ): δ 20.4 (CH 3 ), 55.0 (CH), 121.3, 122.0, 122.2, 122.5, 125.6, 126.4, 126.6, 127.0, 127.1, 127.3, 127.7, 128.0, 128.3, 128.5, 130.4, 130.6, 131.2, 131.9, 132.5, 132.6, 141.1, 141.2, 146.0, 146.1, 148.7, 148.9 (Ar) ., 31 P-NMR (CDCl 3 ): δ 87.2 ( 1 J P-Se = 959.1 Hz). 77 Se-NMR (CDCl 3 ): δ-175.1 ( 1 J Se-P = 959.1 Hz).
<Mass Spectrometry> MS (EI) m / z 619 (M + ).
<Elemental analysis> Anal Calcd for C 36 H 30 NO 2 PSe (619.12): C, 69.90; H, 4.89; N, 2.26. Found: C, 69.84; H, 4.89; N, 2.13.
(Compound 15b)
<Infrared absorption spectrum (KBr tablet)> 3058, 2928, 1957, 1619, 1589, 1506, 1462, 1375, 1321, 1278, 1224, 1201, 1156, 1146, 1069, 792, 748, 717, 696,677, 659, 649, 632, 607, 564, 545, 531, 517cm -1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ 1.65 (d, J = 7.3 Hz, 6H, CH 3 ), 5.11-5.23 (m, 2H, CH) , 6.75-7.97 (m, 22H, Ar)., 13 C-NMR (CDCl 3 ): δ 19.0 (CH 3 ), 55.8 (CH), 120.6, 122.2, 125.2, 125.4, 125.7, 126.0, 126.2, 126.8 , 126.9, 127.1, 127.3, 127.6, 127.8, 127.9, 128.4, 128.5, 130.1, 130.5, 131.3, 131.8, 132.4, 141.5, 141.6, 146.0, 146.1, 148.4, 148.6 (Ar)., 31 P-NMR (CDCl 3 ): Δ 87.8 ( 1 J P-Se = 957.6 Hz). 77 Se-NMR (CDCl 3 ): δ-206.5 ( 1 J Se-P = 957.6 Hz).
<Mass Spectrometry> MS (EI) m / z 619 (M + ).
以上の結果より、化合物15aは下記式(41)に示した構造を有しており、(R,R,R)-ビナフチル-N,N-ビス-1-フェニルエチルセレノリン酸アミドであると同定した。このセレノリン酸アミドの収率は27%(収量:0.501g,0.81mmol)であり、融点は206〜208℃であり、旋光度[α]D 20(c 0.50, CHCl3)は+246°であった。From the above results, compound 15a has the structure shown in the following formula (41), and is (R, R, R) -binaphthyl-N, N-bis-1-phenylethylselenophosphoric acid amide. Identified. The yield of this selenophosphoric acid amide is 27% (yield: 0.501 g, 0.81 mmol), the melting point is 206-208 ° C., and the optical rotation [α] D 20 (c 0.50, CHCl 3 ) is + 246 °. there were.
<赤外吸収スペクトル(KBr錠剤)> 3006, 1588, 1509, 1460, 1433,1355, 1214, 1190, 1157, 1142, 1067, 969, 946, 868, 840, 806, 769, 749, 705, 652cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ7.22-8.32(m,12H, C20H12).、 13C-NMR(CDCl3):δ120.4,121.1, 122.4, 122.6, 126.3, 126.9, 127.0, 127.1, 127.2, 128.7, 131.3, 131.4,132.0, 132.2, 132.3, 132.5, 146.5, 146.6, 147.8, 148.0(Ar).、 31P-NMR(CDCl3):δ69.0(1JP-Se=1060.9Hz).、 77Se-NMR(CDCl3):δ-69.2(d,1JSe-P=1060.9Hz).
<質量分析> MS (EI) m/z 430 (M+).
<元素分析> Anal. Calcd for C20H12ClO2PSe(426.96):C,55.90;H,2.81. Found:C,55.65;H,2.78.
<IR (KBr)> 3006, 1588, 1509, 1460, 1433,1355, 1214, 1190, 1157, 1142, 1067, 969, 946, 868, 840, 806, 769, 749, 705, 652cm - 1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ7.22-8.32 (m, 12H, C 20 H 12 )., 13 C-NMR (CDCl 3 ): δ120 .4,121.1, 122.4, 122.6, 126.3, 126.9, 127.0, 127.1, 127.2, 128.7, 131.3, 131.4,132.0, 132.2, 132.3, 132.5, 146.5, 146.6, 147.8, 148.0 (Ar)., 31 P-NMR (CDCl 3 ): Δ69.0 ( 1 J P-Se = 1060.9 Hz). 77 Se-NMR (CDCl 3 ): δ-69.2 (d, 1 J Se-P = 1060.9 Hz).
<Mass Spectrometry> MS (EI) m / z 430 (M + ).
<Elemental analysis> Anal. Calcd for C 20 H 12 ClO 2 PSe (426.96): C, 55.90; H, 2.81. Found: C, 55.65; H, 2.78.
以上の結果より、化合物16は下記式(43)に示した構造を有しており、(R)-セレノリン酸塩化物であると同定した。このセレノリン酸塩化物の収率は94%(収量:12.12g,28.2mmol)であり、融点は240〜241℃であり、旋光度[α]D 20(c 1.00, CHCl3)は-413°であった。このセレノリン酸塩化物は新規化合物であり、空気中及び水中で安定であった。From the above results, Compound 16 had the structure shown in the following formula (43) and was identified as (R) -selenophosphate chloride. The yield of this selenophosphate is 94% (yield: 12.12 g, 28.2 mmol), the melting point is 240-241 ° C., and the optical rotation [α] D 20 (c 1.00, CHCl 3 ) is −413 °. Met. This selenophosphate chloride is a novel compound and was stable in air and water.
<赤外吸収スペクトル(KBr錠剤)> 3006, 1588, 1509, 1460, 1433,1355, 1214, 1190, 1157, 1142, 1067, 969, 946, 868, 840, 806, 769, 749, 705, 652cm-1
<核磁気共鳴スペクトル(CDCl3溶媒TMS内部標準)> 1H-NMR(CDCl3):δ7.22-8.32(m,12H, C20H12).、 13C-NMR(CDCl3):δ120.4,121.1, 122.4, 122.6, 126.3, 126.9, 127.0, 127.1, 127.2, 128.7, 131.3, 131.4,132.0, 132.2, 132.3, 132.5, 146.5, 146.6, 147.8, 148.0 (Ar).、 31P-NMR(CDCl3):δ69.0(1JP-Se=1060.7Hz).、 77Se-NMR(CDCl3):δ-69.2(d,1JSe-P=1061.0Hz).
<質量分析> MS (EI) m/z 430 (M+).
<元素分析> Anal. Calcd for C20H12ClO2PSe(426.96):C,55.90;H,2.81. Found:C,55.65;H,2.78.
<IR (KBr)> 3006, 1588, 1509, 1460, 1433,1355, 1214, 1190, 1157, 1142, 1067, 969, 946, 868, 840, 806, 769, 749, 705, 652cm - 1
<Nuclear magnetic resonance spectrum (CDCl 3 solvent TMS internal standard)> 1 H-NMR (CDCl 3 ): δ7.22-8.32 (m, 12H, C 20 H 12 )., 13 C-NMR (CDCl 3 ): δ120 .4,121.1, 122.4, 122.6, 126.3, 126.9, 127.0, 127.1, 127.2, 128.7, 131.3, 131.4,132.0, 132.2, 132.3, 132.5, 146.5, 146.6, 147.8, 148.0 (Ar)., 31 P-NMR (CDCl 3 ): Δ69.0 ( 1 J P-Se = 1060.7 Hz). 77 Se-NMR (CDCl 3 ): δ-69.2 (d, 1 J Se-P = 1061.0 Hz).
<Mass Spectrometry> MS (EI) m / z 430 (M + ).
<Elemental analysis> Anal. Calcd for C 20 H 12 ClO 2 PSe (426.96): C, 55.90; H, 2.81. Found: C, 55.65; H, 2.78.
以上の結果より、化合物17は下記式(44)に示した構造を有しており、(S)-セレノリン酸塩化物であると同定した。このセレノリン酸塩化物の収率は90%(収量:11.60g,27.0mmol)であり、融点は240〜241℃であり、旋光度[α]D 20(c 1.00, CHCl3)は+413°であった。このセレノリン酸塩化物は新規化合物であり、空気中及び水中で安定であった。From the above results, Compound 17 had the structure shown in the following formula (44) and was identified as (S) -selenophosphate chloride. The yield of this selenophosphate is 90% (yield: 11.60 g, 27.0 mmol), the melting point is 240-241 ° C., and the optical rotation [α] D 20 (c 1.00, CHCl 3 ) is + 413 °. Met. This selenophosphate chloride is a novel compound and was stable in air and water.
(実施例19) NMRチューブ内に(R)-セレノリン酸塩化物0.026g(0.06mmol)と、ラセミ-2-ブタノール2.75μl(0.03mmol)と、トリエチルアミン8.36μl(0.06mmol)と、0.5mlのCDCl3を加えて反応溶液を調製した後、反応溶液を1時間還流した。そして、反応溶液の31Pの核磁気共鳴スペクトルを測定したところ、78.08ppm及び78.21ppmに、ラセミ-2-ブタノールのCDCl3溶液では観測できなかった新たなシグナルが積分値1:1で観測された。この結果から、(R)-セレノリン酸塩化物がキラル識別化剤として作用することで、ラセミ体であるラセミ-2-ブタノールからキラル化合物を分離可能であることが分かる。Example 19 0.026 g (0.06 mmol) (R) -selenophosphate chloride, 2.75 μl (0.03 mmol) racemic-2-butanol, 8.36 μl (0.06 mmol) triethylamine, 0.5 ml in an NMR tube After adding CDCl 3 to prepare a reaction solution, the reaction solution was refluxed for 1 hour. When the 31 P nuclear magnetic resonance spectrum of the reaction solution was measured, a new signal that could not be observed in the CDCl 3 solution of racemic-2-butanol was observed at 78.08 ppm and 78.21 ppm with an integration value of 1: 1. It was. From this result, it is understood that the chiral compound can be separated from the racemic racemic-2-butanol by the action of (R) -selenophosphoric acid chloride as a chiral discriminating agent.
なお、本実施形態は、次のように変更して具体化することも可能である。
・ 前記セレノホスフィン酸アミドの製造において、セレノホスフィン酸塩化物及びアミンのリチウム塩を低温で同じ溶媒に加えて反応溶液を調製してもよい。前記セレノリン酸アミドの製造において、ビナフチルセレノリン酸クロリドの溶液とアミンの溶液とを低温で混合して反応溶液を調製してもよい。前記三塩化リン、トリエチルアミン、ビナフトール誘導体、及びセレンを低温で同じ溶媒に加えて反応溶液を調製してもよい。このように構成した場合でも各化合物の製造が容易である。In addition, this embodiment can also be changed and embodied as follows.
In the production of the selenophosphinic acid amide, a reaction solution may be prepared by adding selenophosphinic acid chloride and an amine lithium salt to the same solvent at a low temperature. In the production of the selenophosphoric acid amide, a solution of binaphthylselenophosphoric chloride and an amine solution may be mixed at a low temperature to prepare a reaction solution. The phosphorus trichloride, triethylamine, binaphthol derivative, and selenium may be added to the same solvent at a low temperature to prepare a reaction solution. Even in the case of such a configuration, the production of each compound is easy.
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004039043 | 2004-02-16 | ||
JP2004039043 | 2004-02-16 | ||
PCT/JP2004/018380 WO2005077961A1 (en) | 2004-02-16 | 2004-12-09 | Selenophosphinic amides, selenophosphoric amides, selenophosphoric chlorides, and processes for production of them |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005077961A1 JPWO2005077961A1 (en) | 2007-08-02 |
JP4538638B2 true JP4538638B2 (en) | 2010-09-08 |
Family
ID=34857830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005517906A Active JP4538638B2 (en) | 2004-02-16 | 2004-12-09 | Selenophosphate chloride and method for producing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4538638B2 (en) |
WO (1) | WO2005077961A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3763001B2 (en) * | 2003-02-24 | 2006-04-05 | 国立大学法人岐阜大学 | Asymmetric selenophosphinic acid chloride and process for producing the same |
-
2004
- 2004-12-09 WO PCT/JP2004/018380 patent/WO2005077961A1/en active Application Filing
- 2004-12-09 JP JP2005517906A patent/JP4538638B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2005077961A1 (en) | 2007-08-02 |
WO2005077961A1 (en) | 2005-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2975683B2 (en) | Killal phosphoran transition metal catalyst | |
JP4644881B2 (en) | Method for producing ruthenium complex | |
JPWO2007122847A1 (en) | Reagent for organic synthesis, and organic synthesis reaction method using the reagent | |
EP0315886B1 (en) | Isoquinoline derivatives, their manufacture and use | |
JP4538638B2 (en) | Selenophosphate chloride and method for producing the same | |
CN112898218B (en) | Method for synthesizing trifluoromethyl oxazolone compound by one-pot method | |
WO2010047318A1 (en) | Helicene derivative, axially asymmetric amino acid, amine or aminoalcohol derivative, perylene derivative or salt thereof, and methods for producing same | |
JP3445451B2 (en) | Method for producing optically active diphosphine ligand | |
CN101121701B (en) | Five-membered rings 3-position single-substituted benzosultam derivatives and preparation method thereof | |
JP2939510B2 (en) | New asymmetric axially chiral aminophosphine derivatives | |
JP2018534248A (en) | Stereoselective method | |
JP4024059B2 (en) | Binaphthol derivative, chiral zirconium catalyst and asymmetric heterodales alder reaction method | |
JP2003531098A (en) | Preparation of aryl phosphines | |
JP6168665B2 (en) | Pyrophosphate ester compound, bisphosphate ester compound and catalyst | |
CN102933589A (en) | Strecker reagents, their derivatives, methods for forming the same and improved strecker reaction | |
JP7411650B2 (en) | Metal complexes, intermediates, their preparation and use | |
JP3489176B2 (en) | Method for producing optically active organosilicon compound | |
JPS6245238B2 (en) | ||
Shao et al. | College of Chemistry and Molecular Engineering, Zhengzhou University, No. 75, Daxue Road, Zhengzhou City, Henan Province 450052, PR China | |
RU2239639C1 (en) | Achiral bidentate p,n-ligands and method for their preparing | |
JP3866323B2 (en) | Novel N-benzylbenzamide derivatives | |
KR101702870B1 (en) | Synthetic method for (-)-pinidinone | |
JP4257414B2 (en) | Release method of phosphine | |
JP3399507B2 (en) | New palladium-oxazoline pyrazole complex | |
US8877957B2 (en) | Sythesis of P-chiral compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090602 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100311 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100525 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4538638 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |